US20020058254A1 - Screening methods for enzymes and enzyme kits - Google Patents
Screening methods for enzymes and enzyme kits Download PDFInfo
- Publication number
- US20020058254A1 US20020058254A1 US09/753,752 US75375201A US2002058254A1 US 20020058254 A1 US20020058254 A1 US 20020058254A1 US 75375201 A US75375201 A US 75375201A US 2002058254 A1 US2002058254 A1 US 2002058254A1
- Authority
- US
- United States
- Prior art keywords
- dna
- library
- clones
- enzyme
- enzymes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 37
- 238000012216 screening Methods 0.000 title claims abstract description 27
- 102000004190 Enzymes Human genes 0.000 title abstract description 173
- 108090000790 Enzymes Proteins 0.000 title abstract description 173
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 46
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 24
- 230000008569 process Effects 0.000 claims abstract description 10
- 230000001131 transforming effect Effects 0.000 claims abstract description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 17
- 239000007791 liquid phase Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 61
- 239000000126 substance Substances 0.000 abstract description 42
- 244000005700 microbiome Species 0.000 abstract description 36
- 230000004952 protein activity Effects 0.000 abstract 3
- 229940088598 enzyme Drugs 0.000 description 168
- 108020004414 DNA Proteins 0.000 description 132
- 239000000758 substrate Substances 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 239000000523 sample Substances 0.000 description 36
- 239000013598 vector Substances 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- -1 anion cation Chemical class 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 26
- 102000004157 Hydrolases Human genes 0.000 description 24
- 108090000604 Hydrolases Proteins 0.000 description 24
- 108091008053 gene clusters Proteins 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 238000006460 hydrolysis reaction Methods 0.000 description 18
- 241000588724 Escherichia coli Species 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102000053602 DNA Human genes 0.000 description 16
- 230000007062 hydrolysis Effects 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- 229920000936 Agarose Polymers 0.000 description 13
- 230000007613 environmental effect Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 108020004682 Single-Stranded DNA Proteins 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 150000001241 acetals Chemical class 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 238000004806 packaging method and process Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 108090000371 Esterases Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- 239000005018 casein Substances 0.000 description 8
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 8
- 235000021240 caseins Nutrition 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 7
- 108090001060 Lipase Proteins 0.000 description 7
- 239000004367 Lipase Substances 0.000 description 7
- 102000004882 Lipase Human genes 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000002026 chloroform extract Substances 0.000 description 7
- 235000019421 lipase Nutrition 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 108010030975 Polyketide Synthases Proteins 0.000 description 6
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 102000004357 Transferases Human genes 0.000 description 6
- 108090000992 Transferases Proteins 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 5
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 238000006555 catalytic reaction Methods 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 229930001119 polyketide Natural products 0.000 description 5
- 238000003259 recombinant expression Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- QUMXDOLUJCHOAY-UHFFFAOYSA-N 1-Phenylethyl acetate Chemical compound CC(=O)OC(C)C1=CC=CC=C1 QUMXDOLUJCHOAY-UHFFFAOYSA-N 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 4
- 108010061982 DNA Ligases Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 239000007993 MOPS buffer Substances 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000010805 cDNA synthesis kit Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 125000000830 polyketide group Chemical group 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000005809 transesterification reaction Methods 0.000 description 4
- 0 *C(NC(=O)OCC1=CC=CC=C1)C(=O)NC1=CC=C2C(CF)=CC(=O)OC2=C1.CC1=CC=CC=C1.CC1=CNC2=C1C=CC=C2.CCCNC(N)=[NH2+] Chemical compound *C(NC(=O)OCC1=CC=CC=C1)C(=O)NC1=CC=C2C(CF)=CC(=O)OC2=C1.CC1=CC=CC=C1.CC1=CNC2=C1C=CC=C2.CCCNC(N)=[NH2+] 0.000 description 3
- JRHMPHMGOGMNDU-UHFFFAOYSA-N 2-(bromomethyl)-1-methoxy-4-nitrobenzene Chemical compound COC1=CC=C([N+]([O-])=O)C=C1CBr JRHMPHMGOGMNDU-UHFFFAOYSA-N 0.000 description 3
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 3
- PSGQCCSGKGJLRL-UHFFFAOYSA-N 4-methyl-2h-chromen-2-one Chemical group C1=CC=CC2=C1OC(=O)C=C2C PSGQCCSGKGJLRL-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000203069 Archaea Species 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000004195 Isomerases Human genes 0.000 description 3
- 108090000769 Isomerases Proteins 0.000 description 3
- 108090000856 Lyases Proteins 0.000 description 3
- 102000004317 Lyases Human genes 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 239000007984 Tris EDTA buffer Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 150000002118 epoxides Chemical class 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000033444 hydroxylation Effects 0.000 description 3
- 238000005805 hydroxylation reaction Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IELZRWMIHYDLTD-UHFFFAOYSA-N 2-piperidin-3-ylethanamine;dihydrochloride Chemical compound Cl.Cl.NCCC1CCCNC1 IELZRWMIHYDLTD-UHFFFAOYSA-N 0.000 description 2
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical group C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 2
- HXVZGASCDAGAPS-UHFFFAOYSA-N 4-methylumbelliferyl acetate Chemical compound CC1=CC(=O)OC2=CC(OC(=O)C)=CC=C21 HXVZGASCDAGAPS-UHFFFAOYSA-N 0.000 description 2
- WKPUJZVCZXWKCK-UHFFFAOYSA-N 4-methylumbelliferyl butyate Chemical compound CC1=CC(=O)OC2=CC(OC(=O)CCC)=CC=C21 WKPUJZVCZXWKCK-UHFFFAOYSA-N 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 108700023418 Amidases Proteins 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- 108020004634 Archaeal DNA Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 2
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 2
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 2
- FCJSHPDYVMKCHI-UHFFFAOYSA-N O=C(OC1=CC=CC=C1)C1=CC=CC=C1 Chemical compound O=C(OC1=CC=CC=C1)C1=CC=CC=C1 FCJSHPDYVMKCHI-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- 150000001335 aliphatic alkanes Chemical group 0.000 description 2
- 150000001336 alkenes Chemical group 0.000 description 2
- 102000005922 amidase Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 210000003578 bacterial chromosome Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 238000005356 chiral GC Methods 0.000 description 2
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000006735 epoxidation reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- LIIALPBMIOVAHH-UHFFFAOYSA-N herniarin Chemical compound C1=CC(=O)OC2=CC(OC)=CC=C21 LIIALPBMIOVAHH-UHFFFAOYSA-N 0.000 description 2
- JHGVLAHJJNKSAW-UHFFFAOYSA-N herniarin Natural products C1CC(=O)OC2=CC(OC)=CC=C21 JHGVLAHJJNKSAW-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- ZLQJVGSVJRBUNL-UHFFFAOYSA-N methylumbelliferone Natural products C1=C(O)C=C2OC(=O)C(C)=CC2=C1 ZLQJVGSVJRBUNL-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229940016590 sarkosyl Drugs 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 229920001221 xylan Polymers 0.000 description 2
- KIWLGOJGWNJVDN-NCFXGAEVSA-N (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfinyloxane-3,4,5-triol Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1S(=O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 KIWLGOJGWNJVDN-NCFXGAEVSA-N 0.000 description 1
- NKQFKJYKCVDLPT-ZHACJKMWSA-N (4-methyl-2-oxochromen-7-yl) (e)-octadec-9-enoate Chemical compound CC1=CC(=O)OC2=CC(OC(=O)CCCCCCC/C=C/CCCCCCCC)=CC=C21 NKQFKJYKCVDLPT-ZHACJKMWSA-N 0.000 description 1
- NKQFKJYKCVDLPT-KHPPLWFESA-N (4-methyl-2-oxochromen-7-yl) (z)-octadec-9-enoate Chemical compound CC1=CC(=O)OC2=CC(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC=C21 NKQFKJYKCVDLPT-KHPPLWFESA-N 0.000 description 1
- QOIJAZYHGUNKLA-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) octadecanoate Chemical compound CC1=CC(=O)OC2=CC(OC(=O)CCCCCCCCCCCCCCCCC)=CC=C21 QOIJAZYHGUNKLA-UHFFFAOYSA-N 0.000 description 1
- WAPNOHKVXSQRPX-UHFFFAOYSA-N 1-phenylethanol Chemical compound CC(O)C1=CC=CC=C1 WAPNOHKVXSQRPX-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- DEQPBRIACBATHE-FXQIFTODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-iminopentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(=N)C(=O)O)SC[C@@H]21 DEQPBRIACBATHE-FXQIFTODSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- JBNOVHJXQSHGRL-UHFFFAOYSA-N 7-amino-4-(trifluoromethyl)coumarin Chemical compound FC(F)(F)C1=CC(=O)OC2=CC(N)=CC=C21 JBNOVHJXQSHGRL-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 108010006591 Apoenzymes Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- XXMIPYPQZTZIHT-UHFFFAOYSA-N CC(=O)NC(C)C(=O)O.CC(=O)NC(CC1=CC=CC=C1)C(=O)O Chemical compound CC(=O)NC(C)C(=O)O.CC(=O)NC(CC1=CC=CC=C1)C(=O)O XXMIPYPQZTZIHT-UHFFFAOYSA-N 0.000 description 1
- DWZSIFSSLKPTPM-UHFFFAOYSA-N CC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CC(=O)OCC1=CC=CC=C1.CCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCC(=O)OCC1=CC=CC=C1.CCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1 Chemical compound CC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CC(=O)OCC1=CC=CC=C1.CCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCC(=O)OCC1=CC=CC=C1.CCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1 DWZSIFSSLKPTPM-UHFFFAOYSA-N 0.000 description 1
- ORRMWRGNAVANKB-GAJIDSCISA-N CC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCC/C=C/CCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCC/C=C\CCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCCCCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCCCCCCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1 Chemical compound CC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCC/C=C/CCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCC/C=C\CCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCCCCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCCCCCCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1 ORRMWRGNAVANKB-GAJIDSCISA-N 0.000 description 1
- WDVDOUUPQCMSJH-DWEHOVEISA-N CC(=O)OCC1=CC=CC=C1.CCCC(=O)OCC1=CC=CC=C1.CCCCCCCC/C=C\CCCCCCCC(=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCC(=O)OCC1=CC=CC=C1 Chemical compound CC(=O)OCC1=CC=CC=C1.CCCC(=O)OCC1=CC=CC=C1.CCCCCCCC/C=C\CCCCCCCC(=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCCCC(=O)OCC1=CC=CC=C1 WDVDOUUPQCMSJH-DWEHOVEISA-N 0.000 description 1
- CAFULDPKQDKWIN-UHFFFAOYSA-N CC(C(OCc1ccccc1)=O)NC(OCc1ccccc1)=O Chemical compound CC(C(OCc1ccccc1)=O)NC(OCc1ccccc1)=O CAFULDPKQDKWIN-UHFFFAOYSA-N 0.000 description 1
- HZGMSCCFRVGETM-UHFFFAOYSA-N CC(NC(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1.O=C(NC(CC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1 Chemical compound CC(NC(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1.O=C(NC(CC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1)OCC1=CC=CC=C1 HZGMSCCFRVGETM-UHFFFAOYSA-N 0.000 description 1
- FOLIJQAUQJQWOQ-UHFFFAOYSA-N CC1NC(=O)NC1=O.O=C1NC(=O)C(CC2=CC=CC=C2)N1 Chemical compound CC1NC(=O)NC1=O.O=C1NC(=O)C(CC2=CC=CC=C2)N1 FOLIJQAUQJQWOQ-UHFFFAOYSA-N 0.000 description 1
- PTKDIBUNVYIPOD-UHFFFAOYSA-N CCC(C)C(=O)OCC1=CC=CC=C1 Chemical compound CCC(C)C(=O)OCC1=CC=CC=C1 PTKDIBUNVYIPOD-UHFFFAOYSA-N 0.000 description 1
- LSLWNAOQPPLHSW-UHFFFAOYSA-N CCC(C)OC(=O)C1=CC=CC=C1 Chemical compound CCC(C)OC(=O)C1=CC=CC=C1 LSLWNAOQPPLHSW-UHFFFAOYSA-N 0.000 description 1
- GVMVINJAKXSFRA-UHFFFAOYSA-P CCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.NC(=[NH2+])NCCC(NC(=O)OC1=CC=CC=C1)C(=O)NC1=CC=C2C(=C1)OC1=C(C=CC(NC(=O)C(CCNC(N)=[NH2+])NC(=O)OC3=CC=CC=C3)=C1)C21OC(=O)C2=CC=CC=C21 Chemical compound CCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.NC(=[NH2+])NCCC(NC(=O)OC1=CC=CC=C1)C(=O)NC1=CC=C2C(=C1)OC1=C(C=CC(NC(=O)C(CCNC(N)=[NH2+])NC(=O)OC3=CC=CC=C3)=C1)C21OC(=O)C2=CC=CC=C21 GVMVINJAKXSFRA-UHFFFAOYSA-P 0.000 description 1
- UWPLIFBJZRXOGY-QKOLADAJSA-N CCCCCCCC/C=C/CCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCC/C=C\CCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCC/C=C\CCCCCCCC(=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCCCCCCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCCCCCCCCCCCC(=O)OCC1=CC=CC=C1 Chemical compound CCCCCCCC/C=C/CCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCC/C=C\CCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCC/C=C\CCCCCCCC(=O)OCC1=CC=CC=C1.CCCCCCCCCCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCCCCCCCCCCCC(=O)OC1=CC=C2C(C)=CC(=O)OC2=C1.CCCCCCCCCCCCCCCCCC(=O)OCC1=CC=CC=C1 UWPLIFBJZRXOGY-QKOLADAJSA-N 0.000 description 1
- ONKDNNHPWYZAOS-GMFCBQQYSA-N CCCCCCCCC/C=C\CCCCCCCCOC(=O)C1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1 Chemical compound CCCCCCCCC/C=C\CCCCCCCCOC(=O)C1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1 ONKDNNHPWYZAOS-GMFCBQQYSA-N 0.000 description 1
- FWRQUMDONRWNOY-RVVQQURLSA-N CCCCCCCCC/C=C\CCCCCCCCOC(=O)C1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1.CCCOC(=O)C1=CC=CC=C1.COC(=O)C1=CC=CC=C1 Chemical compound CCCCCCCCC/C=C\CCCCCCCCOC(=O)C1=CC=CC=C1.CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1.CCCOC(=O)C1=CC=CC=C1.COC(=O)C1=CC=CC=C1 FWRQUMDONRWNOY-RVVQQURLSA-N 0.000 description 1
- JYRIRSQSAQVJLC-UHFFFAOYSA-N CCCOC(=O)C1=CC=CC=C1.COC(=O)C1=CC=CC=C1 Chemical compound CCCOC(=O)C1=CC=CC=C1.COC(=O)C1=CC=CC=C1 JYRIRSQSAQVJLC-UHFFFAOYSA-N 0.000 description 1
- KCLFZGFHTDNCLL-UHFFFAOYSA-N C[K].O=C(OCC1=CC=CC=C1)C1C=CC(C(=O)OOC2=CC=CC=C2)CC1 Chemical compound C[K].O=C(OCC1=CC=CC=C1)C1C=CC(C(=O)OOC2=CC=CC=C2)CC1 KCLFZGFHTDNCLL-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 108010066072 DNA modification methylase EcoRI Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 102000005486 Epoxide hydrolase Human genes 0.000 description 1
- 108020002908 Epoxide hydrolase Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 102100029203 F-box only protein 8 Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100334493 Homo sapiens FBXO8 gene Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 108010054320 Lignin peroxidase Proteins 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108010033272 Nitrilase Proteins 0.000 description 1
- 108010024026 Nitrile hydratase Proteins 0.000 description 1
- ILHGLRRAUKTLLN-UHFFFAOYSA-N O=C(C(Cc1ccccc1)NC(OCc1ccccc1)=O)OCc1ccccc1 Chemical compound O=C(C(Cc1ccccc1)NC(OCc1ccccc1)=O)OCc1ccccc1 ILHGLRRAUKTLLN-UHFFFAOYSA-N 0.000 description 1
- RDMFCVGTOLJVNI-UHFFFAOYSA-N O=C(O)C1=CC=CC=C1.O=C(OC1CC2CCC1C2)C1=CC=CC=C1 Chemical compound O=C(O)C1=CC=CC=C1.O=C(OC1CC2CCC1C2)C1=CC=CC=C1 RDMFCVGTOLJVNI-UHFFFAOYSA-N 0.000 description 1
- NNLZSROCINYYQB-UHFFFAOYSA-N O=C(OC1C=CC(OC(=O)C2=CC=CC=C2)CC1)C1=CC=CC=C1 Chemical compound O=C(OC1C=CC(OC(=O)C2=CC=CC=C2)CC1)C1=CC=CC=C1 NNLZSROCINYYQB-UHFFFAOYSA-N 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N O=C(OCC1=CC=CC=C1)C1=CC=CC=C1 Chemical compound O=C(OCC1=CC=CC=C1)C1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- HGTGCSNVRVCPRY-UHFFFAOYSA-N O=C(OCC1=CC=CC=C1)C1C2CCC(C2)C12C(=O)O2CC1=CC=CC=C1 Chemical compound O=C(OCC1=CC=CC=C1)C1C2CCC(C2)C12C(=O)O2CC1=CC=CC=C1 HGTGCSNVRVCPRY-UHFFFAOYSA-N 0.000 description 1
- QTQJGYARTUGFJD-UHFFFAOYSA-N O=C1C=C(C(F)(F)F)C2=CC=C(NC(=O)C(CC3=CC=CC=C3)NC(=O)N3CCOCC3)C=C2O1 Chemical compound O=C1C=C(C(F)(F)F)C2=CC=C(NC(=O)C(CC3=CC=CC=C3)NC(=O)N3CCOCC3)C=C2O1 QTQJGYARTUGFJD-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 241000205188 Thermococcus Species 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- GZCGUPFRVQAUEE-UHFFFAOYSA-N alpha-D-galactose Natural products OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- SHZGCJCMOBCMKK-SXUWKVJYSA-N alpha-L-fucose Chemical compound C[C@@H]1O[C@@H](O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-SXUWKVJYSA-N 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000008430 aromatic amides Chemical class 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- SHZGCJCMOBCMKK-FPRJBGLDSA-N beta-D-fucose Chemical compound C[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-FPRJBGLDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-RWOPYEJCSA-N beta-D-mannose Chemical compound OC[C@H]1O[C@@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-RWOPYEJCSA-N 0.000 description 1
- SHZGCJCMOBCMKK-KGJVWPDLSA-N beta-L-fucose Chemical compound C[C@@H]1O[C@H](O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-KGJVWPDLSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000004130 chiral capillary electrophoresis Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 150000001942 cyclopropanes Chemical class 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N hexanedioic acid Natural products OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000009884 interesterification Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 238000006464 oxidative addition reaction Methods 0.000 description 1
- 238000007248 oxidative elimination reaction Methods 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 150000003881 polyketide derivatives Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- UMSVPCYSAUKCAZ-UHFFFAOYSA-N propane;hydrochloride Chemical compound Cl.CCC UMSVPCYSAUKCAZ-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000011945 regioselective hydrolysis Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000003385 ring cleavage reaction Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XCHUIXZPWRRVAH-RRAJOLSVSA-M trimethyl-[4-[(e)-3-(4-methyl-2-oxochromen-7-yl)oxy-3-oxoprop-1-enyl]phenyl]azanium;chloride Chemical compound [Cl-].C1=CC=2C(C)=CC(=O)OC=2C=C1OC(=O)\C=C\C1=CC=C([N+](C)(C)C)C=C1 XCHUIXZPWRRVAH-RRAJOLSVSA-M 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
Definitions
- This invention relates to the field of preparing and screening libraries of clones containing microbially derived DNA and to protein, e.g. enzyme libraries and kits produced therefrom. More particularly, the present invention is directed to recombinant enzyme expression libraries, recombinant enzyme libraries and kits prepared therefrom which recombinant enzymes are generated from DNA obtained from microorganisms.
- recombinant enzymes are generated from microorganisms and are classified by various enzyme characteristics.
- the enzymes can be provided as packaged enzyme screening kits, with enzymes in the kit being grouped to have selected enzyme characteristics.
- a recombinant expression library which is comprised of a multiplicity of clones which are capable of expressing recombinant enzymes.
- the expression library is produced by recovering DNA from a microorganism cloning such DNA into an appropriate expression vector which is then used to transfect or transform an appropriate host for expression of a recombinant protein.
- genomic DNA may be recovered from either a culturable or non-culturable organism and employed to produce an appropriate recombinant expression library for subsequent determination of enzyme activity.
- such recombinant expression library may be prepared without prescreening the organism from which the library is prepared for enzyme activity.
- the polypeptides expressed by such clones are screened for enzyme activity and specified enzyme characteristics in order to identify and classify the recombinant clones which produce polypeptides having specified enzyme characteristics.
- the invention provides a process of screening clones having DNA from an uncultivated microorganism for a specified protein, e.g. enzyme, activity which process comprises:
- screening for a specified protein e.g. enzyme, activity in a library of clones prepared by
- the library is produced from DNA which is recovered without culturing of an organism, particularly where the DNA is recovered from an environmental sample containing microorganisms which are not or cannot be cultured.
- DNA is ligated into a vector, particularly wherein the vector further comprises expression regulatory sequences which can control and regulate the production of a detectable enzyme activity from the ligated DNA.
- the f-factor (or fertility factor) in E. coli is a plasmid which effects high frequency transfer of itself during conjugation and less frequent transfer of the bacterial chromosome itself.
- a particularly preferred embodiment is to use a cloning vector containing an f-factor origin of replication to generate genomic libraries that can be replicated with a high degree of fidelity. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable “environmental DNA library.”
- double stranded DNA obtained from the uncultivated DNA population is selected by:
- the probe may be directly or indirectly bound to a solid phase by which it is separated from single stranded DNA which is not hybridized or otherwise specifically bound to the probe.
- the process can also include releasing single stranded DNA from said probe after recovering said hybridized or otherwise bound single stranded DNA and amplifying the single stranded DNA so released prior to converting it to double stranded DNA.
- the invention also provides a process of screening clones having DNA from an uncultivated microorganisms for a specified protein, e.g. enzyme, activity which comprises screening for a specified gene cluster protein product activity in the library of clones prepared by: (i) recovering DNA from a DNA population derived from at least one uncultivated microorganism; and (ii) transforming a host with recovered DNA to produce a library of clones with the screens for the specified protein, e.g. enzyme, activity.
- the library is produced from gene cluster DNA which is recovered without culturing of an organism, particularly where the DNA gene clusters are recovered from an environmental sample containing microorganisms which are not or cannot be cultured.
- double-stranded gene cluster DNA obtained from the uncultivated DNA population is selected by converting the double-stranded genomic gene cluster DNA into single-stranded DNA; recovering from the converted single-stranded gene cluster polycistron DNA, single-stranded DNA which specifically binds, such as by hybridization, to a polynucleotide probe sequence; and converting recovered single-stranded gene cluster DNA to double-stranded DNA.
- FIG. 1 shows an overview of the procedures used to construct an environmental library from a mixed picoplankion sample as described in Example 3.
- FIG. 2 is a schematic representation of one embodiment of various tiers of chemical characteristics of an enzyme which may be employed in the present invention as described in Example 4.
- FIG. 3 is a schematic representation of another embodiment of various tiers of chemical characteristics of an enzyme which may be employed in the present invention as described in Example 4.
- FIG. 4 is a schematic representation of a further embodiment of various tiers of chemical characteristics of an enzyme which may be employed in the present invention as described in Example 4.
- FIG. 5 is a schematic representation of a still further embodiment of various tiers of chemical characteristics of an enzyme which may be employed in the present invention as described in Example 4.
- FIG. 6 shows the pH optima results produced by enzyme ESL-001-01 in the experiments described in Example 5.
- FIG. 7 shows the temperature optima results produced by enzyme ESL-001-01 in the experiments described in Example 5.
- FIG. 8 shows the organic solvent tolerance results produced by enzyme ESL-001-01 in the experiments described in Example 5.
- the recombinant enzymes are characterized by both physical and chemical characteristics and such chemical characteristics are preferably classified in a tiered manner such that recombinant enzymes having a chemical characteristic in common are then classified by other chemical characteristics which may or may not be more selective or specific chemical characteristic and so on, as hereinafter indicated in more detail.
- the recombinant enzymes are also preferably classified by physical characteristics and one or more tiers of the enzymes which are classified by chemical characteristics may also be classified by physical characteristics or vice versa.
- the term “chemical characteristic” of a recombinant enzyme refers to the substrate or chemical functionality upon which the enzyme acts and/or the catalytic reaction performed by the enzyme; e.g., the catalytic reaction may be hydrolysis (hydrolases) and the chemical functionality may be the type of bond upon which the enzyme acts (esterases cleave ester bonds) or may be the particular type of structure upon which the enzyme acts (a glycosidase which acts on glycosidic bonds).
- a recombinant enzyme which acts on glycosidic bonds may, for example, be chemically classified in accordance with the tiered system as: Tier 1: hydrolase; Tier 2: acetal bonds; Tier 3: glycosidase.
- a “physical characteristic” with respect to a recombinant enzyme means a property (other than a chemical reaction) such as pH; temperature stability; optimum temperature for catalytic reaction: organic solvent tolerance; metal ion selectivity; detergent sensitivity, etc.
- the enzymes at one or more of the chemical characteristic tiers may also be classified by one or more physical characteristics and vice versa.
- the enzymes are classified by both physical and chemical characteristics, e.g., the individual substrates upon which they act as well as physical characteristics.
- a recombinant enzyme which is a protease in this illustration Tier 1 is hydrolase: Tier 2 is amide (peptide bond) that may be further classified in Tier 3 as to the ultimate site in the amino acid sequence where cleavage occurs: e.g., anion cation, large hydrophobic, small hydrophobic.
- Tier 1 is hydrolase
- Tier 2 is amide (peptide bond) that may be further classified in Tier 3 as to the ultimate site in the amino acid sequence where cleavage occurs: e.g., anion cation, large hydrophobic, small hydrophobic.
- Each of the recombinant enzymes which has been classified by the side chain in Tier 3 may also be further classified by physical characteristics of the type hereinabove indicated.
- a recombinant enzyme library prepared from a microorganism is preferably classified by chemical characteristics in a tiered approach. This may be accomplished by initially testing the recombinant polypeptides generated by the library in a low selectivity screen, e.g., the catalytic reaction performed by the enzyme. This may be conveniently accomplished by screening for one or more of the six IUB classes; Oxidoreductases; transferases; hydrolases; lyases, isomerases, ligases.
- the recombinant enzymes which are determined to be positive for one or more of the IUB classes may then be rescreened for a more specific enzyme activity.
- the recombinant library is screened for hydrolase activity
- those recombinant clones which are positive for hydrolase activity may be rescreened for a more specialized hydrolase activity, i.e. the type of bond on which the hydrolase acts.
- the recombinant enzymes which are hydrolases may be rescreened to ascertain those hydrolases which act on one or more specified chemical functionalities, such as: (a) amide (peptide bonds), i.e., proteases: (b) ester bonds, i.e. esterases and lipases; (c) acetals, i.e., glycosidases, etc.
- the recombinant enzymes which have been classified by the chemical bond on which they act may then be rescreened to determine a more specialized activity therefor, such as the type of substrate on which they act.
- those recombinant enzymes which have been classified as acting on ester bonds may be rescreened to determine the ability thereof to generate optically active compounds, i.e., the ability to act on specified substrates, such as meso alcohols, meso diacids, chiral alcohols, chiral acids, etc.
- the recombinant enzymes which have been classified as acting on acetals may be rescreened to classify such recombinant enzymes by a specific type of substrate upon which they act, e.g., (a) P1 sugar such as glucose, galactose, etc., (b) glucose polymer (exo-, endo- or both), etc.
- a specific type of substrate upon which they act e.g., (a) P1 sugar such as glucose, galactose, etc., (b) glucose polymer (exo-, endo- or both), etc.
- TIER 1 Divisions are based upon the catalytic reaction performed by the enzyme, e.g., hydrolysis, reduction, oxidation, etc.
- the six IUB classes will be used: Oxidoreductase. Transferases, Hydrolases, Lyases. Isomerases, Ligases.
- TIER 2 Divisions are based upon the chemical functionality undergoing reaction, e.g., esters, amides, phosphate diesters, sulfate mono esters, aldehydes, ketones, alcohols, acetals, ketals, alkanes, olefins, aromatic rings, heteroaromatic rings, molecular oxygen, enols, etc.
- TIER 3 Divisions and subdivisions are based upon the differences between individual substrate structures which are covalently attached to the functionality undergoing reaction as defined in Tier 2. For example acetal hydrolysis: is the acetal part of glucose or galactose: or is the acetal the ⁇ or ⁇ anomer? These are the types of distinctions made in TIER 3. The divisions based upon substrate specificity are unique to each particular enzyme reaction: there will be different substrate distinctions depending upon whether the enzyme is, for example, a protease or phosphatase
- TIER 4 Divisions are based on which of the two possible enantiomeric products the enzyme produces. This is a measure of the ability of the enzyme to selectively react with one of the two enantiomers (kinetic resolution), or the ability of the enzyme to react with a meso difunctional compound to selectively generate one of the two enantiomeric reaction products.
- TIER 5/ORTHOGONAL TIER/PHYSICAL CHARACTER TIER The fifth tier is orthogonal to the other tiers. It is based on the physical properties of the enzymes, rather than the chemical reactions, per se: The fifth Tier forms a second dimension with which to classify the enzymes. The Fifth Tier can be applied to any of the other Tiers, but will most often be applied to the Third Tier.
- an expression library is randomly produced from the DNA of a microorganism, in particular, the genomic DNA or cDNA of the microorganism and the recombinant proteins or polypeptides produced by such expression library are screened to classify the recombinant enzymes by different enzyme characteristics.
- the recombinant proteins are screened for one or more particular chemical characteristics and the enzymes identified as having such characteristics are then rescreened for a more specific chemical characteristic and this rescreening may be repeated one or more times.
- the recombinant enzymes are also screened to classify such enzymes by one or more physical characteristics.
- the recombinant enzymes generated from the DNA of a microorganism are classified by both chemical and physical characteristics and it is therefore possible to select recombinant enzymes from one or more different organisms that have one or more common chemical characteristics and/or one or more common physical characteristics. Moreover, since such enzymes are recombinant enzymes, it is possible to produce such enzymes in desired quantities and with a desired purity.
- the tiered approach of the present invention is not limited to a tiered approach in which, for example, the tiers are more restrictive.
- the tiered approach is also applicable to using a tiered approach in which, for example, the first tier is “wood degrading” enzymes.
- the second chemical tier could then, for example, be the type of enzyme which is a “wood degrading” enzyme.
- the first tier or any other tier could be physical characteristics and the next tier could he specified chemical characteristics.
- the present invention is generally applicable to providing recombinant enzymes and recombinant enzyme libraries wherein various enzymes are classified by different chemical and/or physical characteristics.
- the microorganisms from which the recombinant libraries may be prepared include prokaryotic microorganisms, such as Eubacteria and Archaebacteria, and lower eukaryotic microorganisms such as fungi, some algae and protozoa.
- the microorganisms may be cultured microorganisms or uncultured microorganisms obtained from environmental samples and such microorganisms may be extremophiles, such as thermophiles, hyperthermophiles, psychrophiles. psychrotrophs, etc.
- the library is produced from DNA which is recovered without culturing of an organism, particularly where the DNA is recovered from an environmental sample containing microorganisms which are not or cannot be cultured.
- Sources of microorganism DNA as a starting material library from which DNA is obtained are particularly contemplated to include environmental samples, such as microbial samples obtained from Arctic and Antarctic ice, water or permafrost sources, materials of volcanic origin, materials from soil or plant sources in tropical areas, etc.
- genomic DNA may be recovered from either uncultured or non-culturable organism and employed to produce an appropriate library of clones for subsequent determination of enzyme activity.
- genes Bacteria and many eukaryotes have a coordinated mechanism for regulating genes whose products are involved in related processes.
- the genes are clustered, in structures referred to as “gene clusters,” on a single chromosome and are transcribed together under the control of a single regulatory sequence, including a single promoter which initiates transcription of the entire cluster.
- the gene cluster, the promoter, and additional sequences that function in regulation altogether are referred to as an “operon” and can include up to 20 or more genes usually from 2 to 6 genes.
- a gene cluster is a group of adjacent genes that are either identical or related, usually as to their function.
- Some gene families consist of identical members. Clustering is a prerequisite for maintaining identity between genes, although clustered genes are not necessarily identical. Gene clusters range from extremes where a duplication is venerated to adjacent related genes to cases where hundreds of identical genes lie in a tandem array. Sometimes no significance is discernable in a repetition of a particular gene. A principal example of this is the expressed duplicate insulin genes in some species. whereas a single insulin gene is adequate in other mammalian species.
- gene clusters undergo continual reorganization and, thus, the ability to create heterogeneous libraries of gene clusters from, for example, bacterial or other prokaryote sources is valuable in determining sources of novel proteins. particularly including proteins, e.g. enzymes, such as, for example, the polyketide synthases that are responsible for the synthesis of polyketides having a vast array of useful activities.
- proteins e.g. enzymes, such as, for example, the polyketide synthases that are responsible for the synthesis of polyketides having a vast array of useful activities.
- Other types of proteins that are the product(s) of gene clusters are also contemplated, including, for example, antibiotics, antivirals, antitumor agents and regulatory proteins, such as insulin.
- Polyketides are molcules which are an extremely rich source of bioactivities, including antibiotics (such as tetracyclines and erythromycin), anti-cancer agents (daunomycin), immunosuppressants (FK506 and rapamycin), and veterinary products (monensin). Many polyketides (produced by polyketide synthases) are valuable as therapeutic agents. Polyketide synthases are multifunctional enzymes that catalyze the biosynthesis of a huge variety of carbon chains differing in length and patterns of functionality and cyclization. Polyketide synthase genes fall into gene clusters and at least one type (designated type I) of polyketide synthases have large size genes and enzymes, complicating genetic manipulation and in vitro studies of these genes/proteins.
- the gene cluster DNA is ligated into a vector, particularly wherein a vector further comprises expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters.
- a vector further comprises expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters.
- Use of vectors which have an exceptionally large capacity for exogenous DNA introduction are particularly appropriate for use with such gene clusters and are described by way of example herein to include the f-factor (or fertility factor) of E. coli .
- This f-factor of E. coli is a plasmid which affect high-frequency transfer of itself during conjugation and is ideal to achieve and stably propagate large DNA fragments, such as gene clusters from mixed microbial samples.
- derived or “isolated” means that material is removed from its original environment (e.g., the natural environment if it is naturally occurring).
- a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide separated from some or all of the coexisting materials in the natural system, is isolated.
- the expression library may be produced from environmental samples in which case DNA may be recovered without culturing of an organism or the DNA may be recovered from a cultured organism.
- genomic DNA may be recovered from either a cultured organism or an environmental sample (for example, soil) by various procedures. The recovered or isolated DNA is then fragmented into a size suitable for producing an expression library and for providing a reasonable probability that desired genes will be expressed and screened without the necessity of screening an excessive number of clones. Thus, for example, if the average genome fragment produced by shearing is 4.5 kbp, for a 1.8 Mbp genome about 2000 clones should be screened to achieve about a 90% probability of obtaining a particular gene. In some cases, in particular where the DNA is recovered without culturing, the DNA is amplified (for example by PCR) after shearing.
- the sized DNA is cloned into an appropriate expression vector and transformed into an appropriate host, preferably a bacterial host and in particular E. coli .
- an appropriate host preferably a bacterial host and in particular E. coli .
- E. coli is preferred, a wide variety of other hosts may be used for producing an expression library.
- the expression vector which is used is preferably one which includes a promoter which is known to function in the selected host in case the native genomic promoter does not function in the host.
- expression vectors which may be used for preparing an expression library there may be mentioned phage, plasmids, phagemids cosmids, phosmids, bacterial artificial chromosomes, P1-based artificial chromosomes, yeast artificial chromosomes, and any other vectors specific for specific hosts of interest (such as bacillus, aspergillus, yeast, etc.)
- the vector may also include a tag of a type known in the art to facilitate purification.
- the probe DNA used for selectively recovering DNA of interest from the DNA derived from the at least one uncultured microorganism can be a full-length coding region sequence or a partial coding region sequence of DNA for an enzyme of known activity, a phylogenetic marker or other identified DNA sequence.
- the original DNA library can be preferably probed using mixtures of probes comprising at least a portion of the DNA sequence encoding the specified activity.
- These probes or probe libraries are preferably single-stranded and the microbial DNA which is probed has preferably been converted into single-stranded form.
- the probes that are particularly suitable are those derived from DNA encoding enzymes having an activity similar or identical to the specified enzyme activity which is to be screened.
- the probe DNA should be at least about 10 bases and preferably at least 15 bases. In one embodiment, the entire coding region may be employed as a probe. Conditions for the hybridization in which DNA is selectively isolated by the use of at least one DNA probe will be designed to provide a hybridization stringency of at least about 50% sequence identity, more particularly a stringency providing for a sequence identity of at least about 70%.
- Hybridization techniques for probing a microbial DNA library to isolate DNA of potential interest are well known in the art and any of those which are described in the literature are suitable for use herein, particularly those which use a solid phase-bound, directly or indirectly bound, probe DNA for ease in separation from the remainder of the DNA derived from the microorganisms.
- the probe DNA is “labeled” with one partner of a specific binding pair (i.e. a ligand) and the other partner of the pair is bound to a solid matrix to provide ease of separation of target from its source.
- the ligand and specific binding partner can be selected from, in either orientation, the following: (1) an antigen or hapten and an antibody or specific binding fragment thereof: (2) biotin or iminobiotin and avidin or streptavidin; (3) a sugar and a lectin specific therefor; (4) an enzyme and an inhibitor therefor; (5) an apoenzyme and cofactor: (6) complementary homopolymeric oligonucleotides; and (7) a hormone and a receptor therefor.
- the solid phase is preferably selected from: (1) a glass or polymeric surface; (2) a packed column of polymeric beads; and (3) magnetic or paramagnetic particles.
- the library of clones prepared as described above can be screened directly for a desired, e.g. enzymatic, activity without the need for culture expansion, amplification or other supplementary procedures. However, in one preferred embodiment, it is considered desirable to amplify the DNA recovered from the individual clones such as by PCR.
- the selectively isolated DNA is separated from the probe DNA after isolation. It is then amplified before being used to transform hosts.
- the double stranded DNA selected to include as at least a portion thereof a predetermined DNA sequence can be rendered single stranded, subjected to amplification and reannealed to provide amplified numbers of selected double stranded DNA. Numerous amplification methodologies are now well known in the art.
- the selected DNA is then used for preparing a library for screening by transforming a suitable organism.
- Hosts particularly those specifically identified herein as preferred, are transformed by artificial introduction of the vectors containing the target DNA by inoculation under conditions conducive for such transformation.
- expression vectors which may be used there may be mentioned viral particles, baculovirus, phage, plasmids, phagemids, cosmids, phosmids, bacterial artificial chromosomes, viral DNA (e.g. vaccinia, adenovirus. foul pox virus, pseudorabies and derivatives of SV40), P1-based artificial chromosomes, yeast plasmids, yeast artificial chromosomes, and any other vectors specific for specific hosts of interest (such as bacillus, aspergillus , yeast, elc.)
- the DNA may be included in any one of a variety of expression vectors for expressing a polypeptide.
- Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences. Large numbers of suitable vectors are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example: Bacterial: pQE70, pQE60, pQE-9 (Qiagen), psiX174, pBluescript SK, pBluescript KS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); pTRC99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG. pSVL (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.
- a particularly preferred type of vector for use in the present invention contains an f-factor origin of replication.
- the f-factor (or fertility factor) in E. coli is a plasmid which effects high frequency transfer of itself during conjugation and less frequent transfer of the bacterial chromosome itself.
- a particularly preferred embodiment is to use cloning vectors, referred to as “fosmids” or bacterial artificial chromosome (BAC) vectors. These are derived from the E. coli f-factor and are able to stably integrate large segments of genomic DNA. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable “environmental DNA library.”
- the DNA derived from a microorganism(s) may be inserted into the vector by a variety of procedures.
- the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.
- the DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis.
- promoter particularly named bacterial promoters include lac, lacZ, T3. T7, gpt, lambda P R , P L and trp.
- Eukaryotic promoters include CMV immediate early. HSV thymidine kinase, early and late SV40. LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.
- the expression vector also contains a ribosome binding site for translation initiation and a transcription terminator.
- the vector may also include appropriate sequences for amplifying expression. Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers.
- the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.
- recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence.
- promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), ⁇ -factor, acid phosphatase, or heat shock proteins. among others.
- PGK 3-phosphoglycerate kinase
- the heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.
- the DNA selected and isolated as hereinabove described is introduced into a suitable host to prepare a library which is screened for the desired enzyme activity.
- the selected DNA is preferably already in a vector which includes appropriate control sequences whereby selected DNA which encodes for an enzyme may be expressed, for detection of the desired activity.
- the host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell.
- Introduction of the construct into the host cell can be effected by transformation, calcium phosphate transfection. DEAE-Dextran mediated transfection, DMSO or electroporation (Davis, L. Dibner, M. Battey, I. Basic Methods in Molecular Biology, (1986)).
- bacterial cells such as E. coli , Bacillus, Streptomyces, Salmonella tryphimurium ; fungal cells, such as yeast: insect cells such as Drosophila S2 and Spodoptera Sf9; animal cells such as CHO. COS or Bowes melanoma: adenoviruses; plant cells, etc.
- fungal cells such as yeast: insect cells such as Drosophila S2 and Spodoptera Sf9
- animal cells such as CHO.
- COS or Bowes melanoma adenoviruses
- plant cells etc.
- the selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.
- Host cells are genetically engineered (transduced or transformed or transfected) with the vectors.
- the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying genes.
- the culture conditions such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
- the recombinant enzymes in the library which are classified as described herein may or may not be sequenced and may or may not be in a purified form.
- the screening for chemical characteristics may be effected on individual expression clones or may be initially effected on a mixture of expression clones to ascertain whether or not the mixture has one or more specified enzyme activities. If the mixture has a specified enzyme activity, then the individual clones may be rescreened for such enzyme activity or for a more specific activity. Thus, for example, if a clone mixture has hydrolase activity, then the individual clones may be recovered and screened to determine which of such clones has hydrolase activity.
- a reagent package or kit is prepared by placing in the kit or package, e.g., in suitable containers, at least three different recombinant enzymes with each of the at least three different recombinant enzymes having at least two enzyme characteristics in common.
- one common characteristic is a chemical characteristic or property and the other common characteristic is a physical characteristic or property: however, it is possible to prepare kits which have two or more chemical characteristics or properties in common and no physical characteristics or property in common and vice versa.
- a variety of enzyme kits or packages can be prepared having a variety of selected chemical and/or physical characteristics which can be formulated to contain three or more recombinant enzymes in which at least three and preferably all of the recombinant enzymes have in common at least one chemical characteristic and have in common at least one physical characteristic.
- the kit should contain an appropriate label specifying such common characteristics.
- kits have in common the most specific chemical characteristic specified on the label.
- label is used in its broadest sense and includes package inserts or literature associated or distributed in conjunction with the kit or package. Thus, for example, if the kit is labeled for a specific substrate (one of the Tier 3 examples above), then for example, at least three of the enzymes in the kit would act on such substrate.
- kits will preferably contain more than three enzymes, for example, five, six or more enzymes and in a preferred embodiment at least three and preferably a majority and in some cases all of the recombinant enzymes in the kit will have at least two enzyme properties or characteristics in common, as hereinabove described.
- the recombinant enzymes in the kits may have two or more enzymes in a single container or individual enzymes in individual containers or various combinations thereof.
- the library may be screened for a specified enzyme activity by procedures known in the art.
- the enzyme activity may be screened for one or more of the six IUB classes; oxidoreductases, transferases, hydrolases, lyases. isomerases and ligases.
- the recombinant enzymes which are determined to be positive for one or more of the IUB classes may then be rescreened for a more specific enzyme activity.
- the library may be screened for a more specialized enzyme activity.
- the library may be screened for a more specialized activity, i.e. the type of bond on which the hydrolase acts.
- the library may be screened to ascertain those hydrolases which act on one or more specified chemical functionalities, such as: (a) amide (peptide bonds), i.e. proteases: (b) ester bonds, i.e. esterases and lipases; (c) acetals, i.e., glycosidases etc.
- the clones which are identified as having the specified enzyme activity may then be sequenced to identify the DNA sequence encoding an enzyme having the specified activity.
- the DNA sequence encoding an enzyme having the specified activity may then be sequenced to identify the DNA sequence encoding an enzyme having the specified activity.
- the screening for enzyme activity may be effected on individual expression clones or may be initially effected on a mixture of expression clones to ascertain whether or not the mixture has one or more specified enzyme activities. If the mixture has a specified enzyme activity, then the individual clones may be rescreened for such enzyme activity or for a more specific activity. Thus, for example, if a clone mixture has hydrolase activity, then the individual clones may be recovered and screened to determine which of such clones has hydrolase activity.
- the expression libraries may be screened for one or more selected chemical characteristics. Selected representative chemical characteristics are described below but such characteristics do not limit the present invention. Moreover, the expression libraries may be screened for some or all of the characteristics. Thus, some of the chemical characteristics specified herein may be determined in all of the libraries, none of the libraries or in only some of the libraries.
- the recombinant enzymes may also be tested and classified by physical properties.
- the recombinant enzymes may be classified by physical properties such as follows:
- the recombinant enzymes of the libraries and kits of the present invention may be used for a variety of purposes and the present invention by providing a plurality of recombinant enzymes classified by a plurality of different enzyme characteristics permits rapid screening of enzymes for a variety of applications.
- the present invention permits assembly of enzyme kits which contain a plurality of enzymes which are capable of operating on a specific bond or a specific substrate at specified conditions to thereby enable screening of enzymes for a variety of applications.
- EcoRi linkers [GGAATTCC] were ligated to the blunted/protected DNA using 10 pmole ends of linkers to 1 pmole end of target DNA.
- the linkers were cut back with EcoRI restriction endonuclease (200 units, 37° C., 1.5 hours) and the DNA size fractionated by sucrose gradient (Maniatis, T., Fritsch, E. F., and Sambrook, J., Molecular Cloning. Cold Spring Harbor Press, New York, 1982).
- the prepared target DNA was ligated to the Lambda ZAP® II vector (Stratagene), packaged using in vitro lambda packaging extracts and grown on XL1-Blue MRF' E. coli strain according to the manufacturer.
- the pBluescript® phagemids were excised from the lambda library, and grown in E. coli DHIOB F' kan, according to the method of Hay and Short (Hav and Short. J. Strategies, 5:16, 1992). The resulting colonies were picked with sterile toothpicks and used to singly inoculate each of the wells of 11 96-well microtiter plates (1056 clones in all).
- the wells contained 250 ⁇ L of LB media with 100 ⁇ g/mL ampicillin. 80 ⁇ g/mL methicillin, and 10% v/v glycerol (LB Amp/Meth, glycerol).
- the cells were grown overnight at 37° C. without shaking. This constituted generation of the “Source Library”; each well of the Source Library thus contained a stock culture of E. coli cells, each of which contained a pBluescript phagemid with a unique DNA insert.
- FIG. 1 shows an overview of the procedures used to construct an environmental library from a mixed picoplankton sample. The goal was to construct a stable, large insert DNA library representing picoplankton genomic DNA.
- Agarose plugs containing concentrated picoplankton cells were prepared from samples collected on an oceanographic cruise from Newport, Oregon to Honolulu. Hi. Seawater (30 liters) was collected in Niskin bottles, screened through 10 Am Nitex, and concentrated by hollow fiber filtration (Amicon DC10) through 30,000 MW cutoff polysulfone filters. The concentrated bacterioplankton cells were collected on a 0.22 ⁇ m, 47 mm Durapore filter, and resuspended in 1 ml of 2 ⁇ STE buffer (1M NaCl, 0. IM EDTA, 10 mM Tris, pH 8.0) to a final density of approximately 1 ⁇ 10 10 cells per ml.
- 2 ⁇ STE buffer (1M NaCl, 0. IM EDTA, 10 mM Tris, pH 8.0
- the cell suspension was mixed with one volume of 1% molten Seaplaque LMP agarose (FMC) cooled to 40° C., and then immediately drawn into a 1 ml syringe.
- the syringe was sealed with parafilm and placed on ice for 10 min.
- the cell-containing agarose plug was extruded into 10 ml of Lysis Buffer (10 mM Tris pH 8.0, 50 mM NaCl, 0.1 M EDTA, 1% Sarkosyl, 0.2% sodium deoxycholate, a mg/ml lysozyme) and incubated at 37° C. for one hour.
- Lysis Buffer 10 mM Tris pH 8.0, 50 mM NaCl, 0.1 M EDTA, 1% Sarkosyl, 0.2% sodium deoxycholate, a mg/ml lysozyme
- the agarose plug was then transferred to 40 mis of ESP Buffer (1% Sarkosyl, 1 mg/ml proteinase-K, in 0.5M EDTA), and incubated at 55° C. for 16 hours. The solution was decanted and replaced with fresh ESP Buffer, and incubated at 55° C. for an additional hour. The agarose plugs were then placed in 50 mM EDTA and stored at 4° C. shipboard for the duration of the oceanographic cruise.
- ESP Buffer 1% Sarkosyl, 1 mg/ml proteinase-K, in 0.5M EDTA
- the solution was then changed to 250 ⁇ l of the same buffer containing 4 U of Sau3AI (NEB), equilibrated to 37° C. in a water bath, and then incubated on a rocking platform in a 37° C. incubator for 45 min.
- the plug was transferred to a 1.5 ml microcentrifuge tube and incubated at 68° C. for 30 min to inactivate the protein, e.g. enzyme, and to melt the agarose.
- the agarose was digested and the DNA dephosphorylased using Gelase and HK-phosphatase (Epicentre), respectively according to the manufacturer s recommendations.
- Protein was removed by gentle phenol/chloroform extraction and the DNA was ethanol precipitated, pelleted, and then washed with 70% ethanol. This partially digested DNA was resuspended in sterile H 2 O to a concentration of 2.5 ng/ ⁇ l for ligation to the pFOSI vector.
- PCR amplification results from several of the agarose plugs indicated the presence of significant amounts of archaeal DNA.
- Agarose plugs prepared from this picoplankton sample were chosen for subsequent fosmid library preparation.
- Each 1 ml agarose plug from this site contained approximately 7.5 ⁇ 10 5 cells, therefore approximately 5.4 ⁇ 10 5 cells were present in the 72 ⁇ l slice used in the preparation of the partially digested DNA.
- Vector arms were prepared from pFOSI as described (Kim et al. Stable propagation of casmid sized human DNA inserts in an F factor based vector. Nucl. Acids Res., 20:10832-10835. 1992). Briefly, the plasmid was completely digested with AstII, dephosphorylated with HK phosphatase, and then digested with BamHI to generate two arms, each of which contained a cos site in the proper orientation for cloning and packaging ligated DNA between 3545 kbp.
- the partially digested picoplankton DNA was ligated overnight to the PFOS1 arms in a 15 ⁇ l ligation reaction containing 25 ng each of vector and insert and 1 U of T4 DNA ligase (Boehringer-Mannheim).
- the ligated DNA in four microliters of this reaction was ill vitro packaged using the Gigapack XL packaging system (Stratagene), the fosmid particles transfected to E. coli strain DHIOB (BRL), and the cells spread onto LB cm15 plates.
- the resultant fosmid clones were picked into 96-well microliter dishes containing LB cm15 supplemented with 7% glycerol. Recombinant fosmids, each containing ca.
- Tier 2 Amide. Ester and Acetal
- Tier 3 Divisions and subdivisions are based upon the differences between individual substrates which are covalently attached to the functionality of Tier 2 undergoing reaction; as well as substrate specificity.
- Tier 4 The two possible enantiomeric products which the enzyme may produce from a substrates
- the eleven plates of the Source Library were used to multiply inoculate a single plate (the “Condensed Plate”) containing in each well 200 ⁇ L of LB Amp/Meth, glycerol. This step was performed using the High Density Replicating Tool (HDRT) of the Beckman Biomek with a 1% bleach water, isopropanol, air-dry sterilization cycle in between each inoculation. Each well of the Condensed Plate thus contained 11 different pBluescript clones from each of the eleven source library plates. The Condensed Plate was grown for 2h at 37° C.
- HDRT High Density Replicating Tool
- a stock solution of 5 mg/mL morphourea phenylalanyl-7-amino-4-trifluoromethyl coumarin (MuPheAFC, the ‘substrate’) in DMSO was diluted to 600 AM with 50 mM pH 7.5 Hepes buffer containing 0.6 mg/mL of the detergent dodecyl maltoside.
- the umbelliferone and rhodamine were added as 600 ⁇ M stock solutions in 50 ⁇ L of Hepes buffer.
- the Tier 1 classification is ‘hydrolase’ and the Tier 2 classification is amide bond. There is no cross reactivity with the Tier 2-ester classification.
- a recombinant clone from the library which has been characterized in Tier 1 as hydrolase and in Tier 2 as amide may then be tested in Tier 3 for various specificities.
- the various classes of Tier 3 are followed by a parenthetical code which identifies the substrates of Table 1 which are used in identifying such specificities of Tier 3.
- a recombinant clone from the library which has been characterized in Tier 1 as hydrolase and in Tier 2 as ester may then be tested in Tier 3 for various specificities.
- the various classes of Tier 3 are followed by a parenthetical code which identifies the substrates of Tables 2 and 2 which are used in identifying such specificities of Tier 3.
- R 2 represents the alcohol portion of the ester and R 1 represents the acid portion of the ester.
- a recombinant clone from the library which has been characterized in Tier 1 as hydrolase and in Tier 2 as acetal may then be tested in Tier 3 for various specificities.
- the various classes of Tier 3 are followed by a parenthetical code which identifies the substrates of Table 4 which are used in identifying such specificities of Tier 3.
- Enzymes may be classified in Tier 4 for the chirality of the product(s) produced by the enzyme.
- chiral amino esters may be determined using at least the following substrates:
- E ln [ ( 1 - c ⁇ ( 1 + ee p ) ] ln [ ( 1 - c ⁇ ( 1 - ee p ) ]
- the enantiomeric excess is determined by either chiral high performance liquid chromatography (HPLC) or chiral capillary electrophoresis (CE). Assays are performed as follows: two hundred ⁇ L of the appropriate buffer is added to each well of a 96-well white microtiter plate, followed by 50 ⁇ L of partially or completely purified enzyme solution, 50 ⁇ L of substrate is added and the increase in fluorescence monitored versus time until 50% of the substrate is consumed or the reaction stops, which ever comes first.
- HPLC high performance liquid chromatography
- CE chiral capillary electrophoresis
- Enantioselectivity was determined for one of the esterases identified as follows. For the reaction to form (transesterification) or breakdown (hydrolysis) ⁇ -methyl benzyl acetate, the enantioselectivity of the enzyme was obtained by determining: ee C (the enantiomeric excess (ee) of the unreacted substrate), ee P (the ee of the hydrolyzed product), and c (the percent conversion of the reaction). The enantiomeric excess was by determined chiral high performance gas chromatography (GC). Chromatography conditions were as follows:
- Sample Preparation Samples were filtered through a 0.2 ⁇ m, 13 mm diameter PTFE filter.
- Oven 90° C. for 1 min, then 90° C. to 150° C at 5° C./min.
- Carrier Gas Helium, 1 mL/min for 2 min then 1 mL/min, to 3 mL/min at 0.2 mL/min.
- the hydrolysis reaction was performed as follows: Fifty ⁇ L of a 10 mM solution of ⁇ -methyl benzyl acetate in 10% aqueous DMSO (v/v) was added to 200 ⁇ L of 100 mM, pH 6.9 phosphate buffer. To this solution was added 250 AL of Enzyme ESL-001-01(2 mg/mL in 100 mM, pH 6.9 phosphate buffer) and the reaction heated at 70° C. for 15 min. The reaction was worked up according to the following procedure: remove 250 ⁇ L of hydrolysis reaction mixture and add to a 1 mL Eppendorf tube. Add 250 AL of ethyl acetate and shake vigorously for 30 seconds. Allow phases to separate for 15 minutes. Pipette off 200 ⁇ L of top organic phase and filter through a 0.2 ⁇ m. 4 mm diameter PTFE filter. Analyze by chiral GC as above.
- This example describes procedures for testing for certain physical characteristics of a recombinant clone of a library.
- Enzyme ESL-001-01 (1:4000 dilution of a 1 mg/mL stock solutions in Hepes buffer) were incubated at 70, 80, and 90° C. At selected time points 25 ⁇ L aliquots were removed and assayed as above in a 96 well microtiter plate with 200 ⁇ L of 100 ⁇ M 4-methylumbelliferyl palmitate and 0.6 mg/mL dodecyl maltoside. This data was used to determine the half life for inactivation of the enzyme.
- Enzyme ESL-001-01 gave the following results: Temperature Half Life 90 23 min. 80 32 min. 70 110 h
- the specific activity was determined using 100 ⁇ M 4-methyl umbelliferyl heptanoate at 90° C. in pH 6.9 MOPS buffer.
- the specific activity obtained for Enzyme ESL-001-01 was 1662 ⁇ mol/min mg.
- This example describes procedures for testing for substrate specificity of a recombinant clone of a library.
- AMC 7-amino-4-methyl coumarin
- AD3 Fluorescein conjugated casein t-BOC-Ala-Ala-Asp-AFC CBZ-Ala-Ala-Lys-AFC succinyl-Ala-Ala-Phe-AFC succinyl-Ala-Gly-Leu-AFC
- AFC 7-amino-4-trifluoromethyl coumarin.)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Recombinant enzyme libraries and kits where a plurality of enzymes are each characterized by different physical and/or chemical characteristics and classified by common characteristics. The characteristics are determined by screening of recombinant enzymes expressed by a DNA library produced from various microorganisms. Also disclosed is a process for identifying clones of a recombinant library which express a protein with a desired ctivity by screening a library of expression clones randomly produced from DNA of at least one microorganism, said screeing being effected on expression products of said clones to thereby identify clones which express a protein with a desired activity. Also disclosed is a process of screening clones having DNA from an uncultivatedmicroorganism for a specified protein activity by screening for a specified protein activity in a library of clones prepared by (I) recovering DNA from a DNA population derived from at least one uncultivated microorganism; and (ii) transforming a host with recovered DNA to produce a library of clones which is screened for the specified protein activity.
Description
- This invention relates to the field of preparing and screening libraries of clones containing microbially derived DNA and to protein, e.g. enzyme libraries and kits produced therefrom. More particularly, the present invention is directed to recombinant enzyme expression libraries, recombinant enzyme libraries and kits prepared therefrom which recombinant enzymes are generated from DNA obtained from microorganisms.
- Industry has recognized the need for new enzymes for a wide variety of industrial applications. As a result, a variety of microorganisms have been screened to ascertain whether or not such microorganisms have a desired enzyme activity. If such microorganism does have a desired enzyme activity, the enzyme is then recovered from the microorganism.
- Naturally occurring assemblages of microorganisms often encompass a bewildering array of physiological and metabolic diversity. In fact, it has been estimated that to date less than one percent of the world's organisms have been cultured. It has been suggested that a large fraction of this diversity thus far has been unrecognized due to difficulties in enriching and isolating microorganisms in pure culture. Therefore, it has been difficult or impossible to identify or isolate valuable enzymes from these samples. These limitations suggest the need for alternative approaches to characterize the physiological and metabolic potential i.e. activities of interest of as-yet uncultivated microorganisms, which to date have been characterized solely by analyses of PCR amplified rRNA gene fragments, clonally recovered from mixed assemblage nucleic acids.
- In accordance with one aspect of the present invention, there is provided a novel approach for obtaining enzymes for further use, for example, for packaging into kits for further research. In accordance with the present invention, recombinant enzymes are generated from microorganisms and are classified by various enzyme characteristics. In this manner, the enzymes can be provided as packaged enzyme screening kits, with enzymes in the kit being grouped to have selected enzyme characteristics.
- More particularly, in accordance with this aspect of the present invention there is provided a recombinant expression library which is comprised of a multiplicity of clones which are capable of expressing recombinant enzymes. The expression library is produced by recovering DNA from a microorganism cloning such DNA into an appropriate expression vector which is then used to transfect or transform an appropriate host for expression of a recombinant protein.
- Thus, for example, genomic DNA may be recovered from either a culturable or non-culturable organism and employed to produce an appropriate recombinant expression library for subsequent determination of enzyme activity.
- In accordance with an aspect of the present invention, such recombinant expression library may be prepared without prescreening the organism from which the library is prepared for enzyme activity.
- Having prepared a multiplicity of recombinant expression clones from DNA isolated from an organism, the polypeptides expressed by such clones are screened for enzyme activity and specified enzyme characteristics in order to identify and classify the recombinant clones which produce polypeptides having specified enzyme characteristics.
- In one aspect, the invention provides a process of screening clones having DNA from an uncultivated microorganism for a specified protein, e.g. enzyme, activity which process comprises:
- screening for a specified protein, e.g. enzyme, activity in a library of clones prepared by
- (i) recovering DNA from a DNA population derived from at least one uncultivated microorganism and
- (ii) transforming a host with recovered DNA to produce a library of clones which are screened for the specified protein, e.g. enzyme. activity.
- The library is produced from DNA which is recovered without culturing of an organism, particularly where the DNA is recovered from an environmental sample containing microorganisms which are not or cannot be cultured.
- In a preferred embodiment of this aspect DNA is ligated into a vector, particularly wherein the vector further comprises expression regulatory sequences which can control and regulate the production of a detectable enzyme activity from the ligated DNA.
- The f-factor (or fertility factor) inE. coli is a plasmid which effects high frequency transfer of itself during conjugation and less frequent transfer of the bacterial chromosome itself. To archieve and stably propogate large DNA fragments from mixed microbial samples, a particularly preferred embodiment is to use a cloning vector containing an f-factor origin of replication to generate genomic libraries that can be replicated with a high degree of fidelity. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable “environmental DNA library.”
- In another preferred embodiment, double stranded DNA obtained from the uncultivated DNA population is selected by:
- converting the double stranded genomic DNA into single stranded DNA:
- recovering from the converted single stranded DNA single stranded DNA which specifically binds, such as by hybridization, to a probe DNA sequence: and
- converting recovered single stranded DNA to double stranded DNA.
- The probe may be directly or indirectly bound to a solid phase by which it is separated from single stranded DNA which is not hybridized or otherwise specifically bound to the probe.
- The process can also include releasing single stranded DNA from said probe after recovering said hybridized or otherwise bound single stranded DNA and amplifying the single stranded DNA so released prior to converting it to double stranded DNA.
- The invention also provides a process of screening clones having DNA from an uncultivated microorganisms for a specified protein, e.g. enzyme, activity which comprises screening for a specified gene cluster protein product activity in the library of clones prepared by: (i) recovering DNA from a DNA population derived from at least one uncultivated microorganism; and (ii) transforming a host with recovered DNA to produce a library of clones with the screens for the specified protein, e.g. enzyme, activity. The library is produced from gene cluster DNA which is recovered without culturing of an organism, particularly where the DNA gene clusters are recovered from an environmental sample containing microorganisms which are not or cannot be cultured.
- Alternatively, double-stranded gene cluster DNA obtained from the uncultivated DNA population is selected by converting the double-stranded genomic gene cluster DNA into single-stranded DNA; recovering from the converted single-stranded gene cluster polycistron DNA, single-stranded DNA which specifically binds, such as by hybridization, to a polynucleotide probe sequence; and converting recovered single-stranded gene cluster DNA to double-stranded DNA.
- These and other aspects of the present invention are described with respect to particular preferred embodiments and will be apparent to those skilled in the art from the teachings herein.
- FIG. 1 shows an overview of the procedures used to construct an environmental library from a mixed picoplankion sample as described in Example 3.
- FIG. 2 is a schematic representation of one embodiment of various tiers of chemical characteristics of an enzyme which may be employed in the present invention as described in Example 4.
- FIG. 3 is a schematic representation of another embodiment of various tiers of chemical characteristics of an enzyme which may be employed in the present invention as described in Example 4.
- FIG. 4 is a schematic representation of a further embodiment of various tiers of chemical characteristics of an enzyme which may be employed in the present invention as described in Example 4.
- FIG. 5 is a schematic representation of a still further embodiment of various tiers of chemical characteristics of an enzyme which may be employed in the present invention as described in Example 4.
- FIG. 6 shows the pH optima results produced by enzyme ESL-001-01 in the experiments described in Example 5.
- FIG. 7 shows the temperature optima results produced by enzyme ESL-001-01 in the experiments described in Example 5.
- FIG. 8 shows the organic solvent tolerance results produced by enzyme ESL-001-01 in the experiments described in Example 5.
- DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
- In accordance with a preferred aspect of the present invention, the recombinant enzymes are characterized by both physical and chemical characteristics and such chemical characteristics are preferably classified in a tiered manner such that recombinant enzymes having a chemical characteristic in common are then classified by other chemical characteristics which may or may not be more selective or specific chemical characteristic and so on, as hereinafter indicated in more detail.
- As hereinabove indicated, the recombinant enzymes are also preferably classified by physical characteristics and one or more tiers of the enzymes which are classified by chemical characteristics may also be classified by physical characteristics or vice versa.
- As used herein, the term “chemical characteristic” of a recombinant enzyme refers to the substrate or chemical functionality upon which the enzyme acts and/or the catalytic reaction performed by the enzyme; e.g., the catalytic reaction may be hydrolysis (hydrolases) and the chemical functionality may be the type of bond upon which the enzyme acts (esterases cleave ester bonds) or may be the particular type of structure upon which the enzyme acts (a glycosidase which acts on glycosidic bonds). Thus, for example, a recombinant enzyme which acts on glycosidic bonds may, for example, be chemically classified in accordance with the tiered system as: Tier 1: hydrolase; Tier 2: acetal bonds; Tier 3: glycosidase.
- As used herein a “physical characteristic” with respect to a recombinant enzyme means a property (other than a chemical reaction) such as pH; temperature stability; optimum temperature for catalytic reaction: organic solvent tolerance; metal ion selectivity; detergent sensitivity, etc.
- In an embodiment of the invention, in which a tiered approach is employed for classifying the recombinant enzymes by chemical and/or physical characteristics, the enzymes at one or more of the chemical characteristic tiers may also be classified by one or more physical characteristics and vice versa. In a preferred embodiment, the enzymes are classified by both physical and chemical characteristics, e.g., the individual substrates upon which they act as well as physical characteristics.
- Thus, for example, as a representative example of the manner in which a recombinant enzyme may be classified in accordance with the present invention, a recombinant enzyme which is a protease (in this
illustration Tier 1 is hydrolase:Tier 2 is amide (peptide bond) that may be further classified inTier 3 as to the ultimate site in the amino acid sequence where cleavage occurs: e.g., anion cation, large hydrophobic, small hydrophobic. Each of the recombinant enzymes which has been classified by the side chain inTier 3 may also be further classified by physical characteristics of the type hereinabove indicated. - In this manner, it is possible to select from the recombinant library, enzymes which have a specified chemical characteristic in common, e.g., all endopeptidases (which act on internal peptide bonds) and which have a specified physical characteristic in common, e.g., all act optimally at a pH within a specified range.
- As hereinabove indicated, a recombinant enzyme library prepared from a microorganism is preferably classified by chemical characteristics in a tiered approach. This may be accomplished by initially testing the recombinant polypeptides generated by the library in a low selectivity screen, e.g., the catalytic reaction performed by the enzyme. This may be conveniently accomplished by screening for one or more of the six IUB classes; Oxidoreductases; transferases; hydrolases; lyases, isomerases, ligases.
- The recombinant enzymes which are determined to be positive for one or more of the IUB classes may then be rescreened for a more specific enzyme activity.
- Thus, for example, if the recombinant library is screened for hydrolase activity, then those recombinant clones which are positive for hydrolase activity may be rescreened for a more specialized hydrolase activity, i.e. the type of bond on which the hydrolase acts. Thus, for example, the recombinant enzymes which are hydrolases may be rescreened to ascertain those hydrolases which act on one or more specified chemical functionalities, such as: (a) amide (peptide bonds), i.e., proteases: (b) ester bonds, i.e. esterases and lipases; (c) acetals, i.e., glycosidases, etc.
- The recombinant enzymes which have been classified by the chemical bond on which they act may then be rescreened to determine a more specialized activity therefor, such as the type of substrate on which they act.
- Thus, for example, those recombinant enzymes which have been classified as acting on ester bonds (lipases and esterases) may be rescreened to determine the ability thereof to generate optically active compounds, i.e., the ability to act on specified substrates, such as meso alcohols, meso diacids, chiral alcohols, chiral acids, etc.
- For example, the recombinant enzymes which have been classified as acting on acetals may be rescreened to classify such recombinant enzymes by a specific type of substrate upon which they act, e.g., (a) P1 sugar such as glucose, galactose, etc., (b) glucose polymer (exo-, endo- or both), etc.
- Enzyme Tiers
- Thus, as a representative but not limiting example, the following are representative enzyme tiers:
-
TIER 1. Divisions are based upon the catalytic reaction performed by the enzyme, e.g., hydrolysis, reduction, oxidation, etc. The six IUB classes will be used: Oxidoreductase. Transferases, Hydrolases, Lyases. Isomerases, Ligases. - TIER 2: Divisions are based upon the chemical functionality undergoing reaction, e.g., esters, amides, phosphate diesters, sulfate mono esters, aldehydes, ketones, alcohols, acetals, ketals, alkanes, olefins, aromatic rings, heteroaromatic rings, molecular oxygen, enols, etc.
- Lipases and esterases both cleave the ester bond: the distinction comes in whether the natural substrate is aggregated into a membrane (lipases) or dispersed into solution (esterases).
- TIER 3: Divisions and subdivisions are based upon the differences between individual substrate structures which are covalently attached to the functionality undergoing reaction as defined in
Tier 2. For example acetal hydrolysis: is the acetal part of glucose or galactose: or is the acetal the α or β anomer? These are the types of distinctions made inTIER 3. The divisions based upon substrate specificity are unique to each particular enzyme reaction: there will be different substrate distinctions depending upon whether the enzyme is, for example, a protease or phosphatase - TIER 4: Divisions are based on which of the two possible enantiomeric products the enzyme produces. This is a measure of the ability of the enzyme to selectively react with one of the two enantiomers (kinetic resolution), or the ability of the enzyme to react with a meso difunctional compound to selectively generate one of the two enantiomeric reaction products.
- TIER 5/ORTHOGONAL TIER/PHYSICAL CHARACTER TIER. The fifth tier is orthogonal to the other tiers. It is based on the physical properties of the enzymes, rather than the chemical reactions, per se: The fifth Tier forms a second dimension with which to classify the enzymes. The Fifth Tier can be applied to any of the other Tiers, but will most often be applied to the Third Tier.
- Thus, in accordance with an aspect of the present invention, an expression library is randomly produced from the DNA of a microorganism, in particular, the genomic DNA or cDNA of the microorganism and the recombinant proteins or polypeptides produced by such expression library are screened to classify the recombinant enzymes by different enzyme characteristics. In a preferred embodiment, the recombinant proteins are screened for one or more particular chemical characteristics and the enzymes identified as having such characteristics are then rescreened for a more specific chemical characteristic and this rescreening may be repeated one or more times. In addition, in a preferred embodiment, the recombinant enzymes are also screened to classify such enzymes by one or more physical characteristics. In this manner, the recombinant enzymes generated from the DNA of a microorganism are classified by both chemical and physical characteristics and it is therefore possible to select recombinant enzymes from one or more different organisms that have one or more common chemical characteristics and/or one or more common physical characteristics. Moreover, since such enzymes are recombinant enzymes, it is possible to produce such enzymes in desired quantities and with a desired purity.
- The tiered approach of the present invention is not limited to a tiered approach in which, for example, the tiers are more restrictive. For example, the tiered approach is also applicable to using a tiered approach in which, for example, the first tier is “wood degrading” enzymes. The second chemical tier could then, for example, be the type of enzyme which is a “wood degrading” enzyme.
- Similarly, the first tier or any other tier could be physical characteristics and the next tier could he specified chemical characteristics.
- Thus, the present invention is generally applicable to providing recombinant enzymes and recombinant enzyme libraries wherein various enzymes are classified by different chemical and/or physical characteristics.
- The microorganisms from which the recombinant libraries may be prepared include prokaryotic microorganisms, such as Eubacteria and Archaebacteria, and lower eukaryotic microorganisms such as fungi, some algae and protozoa. The microorganisms may be cultured microorganisms or uncultured microorganisms obtained from environmental samples and such microorganisms may be extremophiles, such as thermophiles, hyperthermophiles, psychrophiles. psychrotrophs, etc.
- Preferably, the library is produced from DNA which is recovered without culturing of an organism, particularly where the DNA is recovered from an environmental sample containing microorganisms which are not or cannot be cultured. Sources of microorganism DNA as a starting material library from which DNA is obtained are particularly contemplated to include environmental samples, such as microbial samples obtained from Arctic and Antarctic ice, water or permafrost sources, materials of volcanic origin, materials from soil or plant sources in tropical areas, etc. Thus, for example, genomic DNA may be recovered from either uncultured or non-culturable organism and employed to produce an appropriate library of clones for subsequent determination of enzyme activity.
- Bacteria and many eukaryotes have a coordinated mechanism for regulating genes whose products are involved in related processes. The genes are clustered, in structures referred to as “gene clusters,” on a single chromosome and are transcribed together under the control of a single regulatory sequence, including a single promoter which initiates transcription of the entire cluster. The gene cluster, the promoter, and additional sequences that function in regulation altogether are referred to as an “operon” and can include up to 20 or more genes usually from 2 to 6 genes. Thus, a gene cluster is a group of adjacent genes that are either identical or related, usually as to their function.
- Some gene families consist of identical members. Clustering is a prerequisite for maintaining identity between genes, although clustered genes are not necessarily identical. Gene clusters range from extremes where a duplication is venerated to adjacent related genes to cases where hundreds of identical genes lie in a tandem array. Sometimes no significance is discernable in a repetition of a particular gene. A principal example of this is the expressed duplicate insulin genes in some species. whereas a single insulin gene is adequate in other mammalian species.
- It is important to further research gene clusters and the extent to which the full length of the cluster is necessary for the expression of the proteins resulting therefrom. Further, gene clusters undergo continual reorganization and, thus, the ability to create heterogeneous libraries of gene clusters from, for example, bacterial or other prokaryote sources is valuable in determining sources of novel proteins. particularly including proteins, e.g. enzymes, such as, for example, the polyketide synthases that are responsible for the synthesis of polyketides having a vast array of useful activities. Other types of proteins that are the product(s) of gene clusters are also contemplated, including, for example, antibiotics, antivirals, antitumor agents and regulatory proteins, such as insulin.
- Polyketides are molcules which are an extremely rich source of bioactivities, including antibiotics (such as tetracyclines and erythromycin), anti-cancer agents (daunomycin), immunosuppressants (FK506 and rapamycin), and veterinary products (monensin). Many polyketides (produced by polyketide synthases) are valuable as therapeutic agents. Polyketide synthases are multifunctional enzymes that catalyze the biosynthesis of a huge variety of carbon chains differing in length and patterns of functionality and cyclization. Polyketide synthase genes fall into gene clusters and at least one type (designated type I) of polyketide synthases have large size genes and enzymes, complicating genetic manipulation and in vitro studies of these genes/proteins.
- The ability to select and combine desired components from a library of polyketide and postpolyketide biosynthesis genes for generation of novel polyketides for study is appealing. Using the method(s) of the present invention facilitates the cloning of novel polyketide synthases, particularly when one uses the f-factor based vectors, which facilitate cloning of gene clusters.
- Preferably, the gene cluster DNA is ligated into a vector, particularly wherein a vector further comprises expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters. Use of vectors which have an exceptionally large capacity for exogenous DNA introduction are particularly appropriate for use with such gene clusters and are described by way of example herein to include the f-factor (or fertility factor) ofE. coli. This f-factor of E. coli is a plasmid which affect high-frequency transfer of itself during conjugation and is ideal to achieve and stably propagate large DNA fragments, such as gene clusters from mixed microbial samples.
- The term “derived” or “isolated” means that material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide separated from some or all of the coexisting materials in the natural system, is isolated.
- As hereinabove indicated, the expression library may be produced from environmental samples in which case DNA may be recovered without culturing of an organism or the DNA may be recovered from a cultured organism.
- In preparing the expression library genomic DNA may be recovered from either a cultured organism or an environmental sample (for example, soil) by various procedures. The recovered or isolated DNA is then fragmented into a size suitable for producing an expression library and for providing a reasonable probability that desired genes will be expressed and screened without the necessity of screening an excessive number of clones. Thus, for example, if the average genome fragment produced by shearing is 4.5 kbp, for a 1.8 Mbp genome about 2000 clones should be screened to achieve about a 90% probability of obtaining a particular gene. In some cases, in particular where the DNA is recovered without culturing, the DNA is amplified (for example by PCR) after shearing.
- The sized DNA is cloned into an appropriate expression vector and transformed into an appropriate host, preferably a bacterial host and in particularE. coli. Although E. coli is preferred, a wide variety of other hosts may be used for producing an expression library.
- The expression vector which is used is preferably one which includes a promoter which is known to function in the selected host in case the native genomic promoter does not function in the host.
- As representative examples of expression vectors which may be used for preparing an expression library there may be mentioned phage, plasmids, phagemids cosmids, phosmids, bacterial artificial chromosomes, P1-based artificial chromosomes, yeast artificial chromosomes, and any other vectors specific for specific hosts of interest (such asbacillus, aspergillus, yeast, etc.) The vector may also include a tag of a type known in the art to facilitate purification.
- The following outlines a general procedure for producing expression libraries from both culturable and non-culturable organisms.
- CULTURABLE ORGANISMS
- Obtain Biomass
- DNA Isolation (CTAB)
- Shear DNA (25 gauze needle)
- Blunt DNA (Mung Bean Nuclease)
- Methylate (Eco RI Methylase)
- Ligate to Eco RI linkers (GGAATTCC)
- Cut back linkers (Eco RI Restriction Endonuclease)
- Size Fractionate (Sucrose Gradient)
- Ligate to lambda vector (Lambda ZAP II and gt11)
- Package (in vitro lambda packaging extract)
- Plate onE. coli host and amplify
- UNCULTURABLE ORGANISMS
- Obtain cells
- Isolate DNA (Various Methods)
- Blunt DNA (Mung Bean Nuclease)
- Ligate to adaptor containing a Not I site and conjugated to magnetic beads
- Ligate unconjugated adaptor to the other end of the DNA
- Amplify DNA in a reaction which allows for high fidelity, and uses adaptor sequences as primers
- Cut DNA with Not I
- Size fractionate (Sucrose Gradient or Sephacryl Column)
- Ligate to lambda vector (Lambda ZAP II and gt11)
- Package (in vitro lambda packaging extract)
- Plate onE. Coli host and amplify
- The probe DNA used for selectively recovering DNA of interest from the DNA derived from the at least one uncultured microorganism can be a full-length coding region sequence or a partial coding region sequence of DNA for an enzyme of known activity, a phylogenetic marker or other identified DNA sequence. The original DNA library can be preferably probed using mixtures of probes comprising at least a portion of the DNA sequence encoding the specified activity. These probes or probe libraries are preferably single-stranded and the microbial DNA which is probed has preferably been converted into single-stranded form. The probes that are particularly suitable are those derived from DNA encoding enzymes having an activity similar or identical to the specified enzyme activity which is to be screened.
- The probe DNA should be at least about 10 bases and preferably at least 15 bases. In one embodiment, the entire coding region may be employed as a probe. Conditions for the hybridization in which DNA is selectively isolated by the use of at least one DNA probe will be designed to provide a hybridization stringency of at least about 50% sequence identity, more particularly a stringency providing for a sequence identity of at least about 70%.
- Hybridization techniques for probing a microbial DNA library to isolate DNA of potential interest are well known in the art and any of those which are described in the literature are suitable for use herein, particularly those which use a solid phase-bound, directly or indirectly bound, probe DNA for ease in separation from the remainder of the DNA derived from the microorganisms.
- Preferably the probe DNA is “labeled” with one partner of a specific binding pair (i.e. a ligand) and the other partner of the pair is bound to a solid matrix to provide ease of separation of target from its source. The ligand and specific binding partner can be selected from, in either orientation, the following: (1) an antigen or hapten and an antibody or specific binding fragment thereof: (2) biotin or iminobiotin and avidin or streptavidin; (3) a sugar and a lectin specific therefor; (4) an enzyme and an inhibitor therefor; (5) an apoenzyme and cofactor: (6) complementary homopolymeric oligonucleotides; and (7) a hormone and a receptor therefor. The solid phase is preferably selected from: (1) a glass or polymeric surface; (2) a packed column of polymeric beads; and (3) magnetic or paramagnetic particles.
- The library of clones prepared as described above can be screened directly for a desired, e.g. enzymatic, activity without the need for culture expansion, amplification or other supplementary procedures. However, in one preferred embodiment, it is considered desirable to amplify the DNA recovered from the individual clones such as by PCR.
- Further, it is optional but desirable to perform an amplification of the target DNA that has been isolated. In this embodiment the selectively isolated DNA is separated from the probe DNA after isolation. It is then amplified before being used to transform hosts. The double stranded DNA selected to include as at least a portion thereof a predetermined DNA sequence can be rendered single stranded, subjected to amplification and reannealed to provide amplified numbers of selected double stranded DNA. Numerous amplification methodologies are now well known in the art.
- The selected DNA is then used for preparing a library for screening by transforming a suitable organism. Hosts, particularly those specifically identified herein as preferred, are transformed by artificial introduction of the vectors containing the target DNA by inoculation under conditions conducive for such transformation.
- As representative examples of expression vectors which may be used there may be mentioned viral particles, baculovirus, phage, plasmids, phagemids, cosmids, phosmids, bacterial artificial chromosomes, viral DNA (e.g. vaccinia, adenovirus. foul pox virus, pseudorabies and derivatives of SV40), P1-based artificial chromosomes, yeast plasmids, yeast artificial chromosomes, and any other vectors specific for specific hosts of interest (such asbacillus, aspergillus, yeast, elc.) Thus, for example, the DNA may be included in any one of a variety of expression vectors for expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences. Large numbers of suitable vectors are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example: Bacterial: pQE70, pQE60, pQE-9 (Qiagen), psiX174, pBluescript SK, pBluescript KS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); pTRC99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG. pSVL (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.
- A particularly preferred type of vector for use in the present invention contains an f-factor origin of replication. The f-factor (or fertility factor) inE. coli is a plasmid which effects high frequency transfer of itself during conjugation and less frequent transfer of the bacterial chromosome itself. A particularly preferred embodiment is to use cloning vectors, referred to as “fosmids” or bacterial artificial chromosome (BAC) vectors. These are derived from the E. coli f-factor and are able to stably integrate large segments of genomic DNA. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable “environmental DNA library.”
- The DNA derived from a microorganism(s) may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.
- The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. Particular named bacterial promoters include lac, lacZ, T3. T7, gpt, lambda PR, PL and trp. Eukaryotic promoters include CMV immediate early. HSV thymidine kinase, early and late SV40. LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers.
- In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance inE. coli.
- Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene ofE. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), α-factor, acid phosphatase, or heat shock proteins. among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.
- The DNA selected and isolated as hereinabove described is introduced into a suitable host to prepare a library which is screened for the desired enzyme activity. The selected DNA is preferably already in a vector which includes appropriate control sequences whereby selected DNA which encodes for an enzyme may be expressed, for detection of the desired activity. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by transformation, calcium phosphate transfection. DEAE-Dextran mediated transfection, DMSO or electroporation (Davis, L. Dibner, M. Battey, I. Basic Methods in Molecular Biology, (1986)).
- As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such asE. coli, Bacillus, Streptomyces, Salmonella tryphimurium; fungal cells, such as yeast: insect cells such as Drosophila S2 and Spodoptera Sf9; animal cells such as CHO. COS or Bowes melanoma: adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.
- Host cells are genetically engineered (transduced or transformed or transfected) with the vectors. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying genes. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
- The recombinant enzymes in the library which are classified as described herein may or may not be sequenced and may or may not be in a purified form. Thus, in accordance with the present invention, it is possible to classify one or more of the recombinant enzymes before or after obtaining the sequence of the enzyme or before or after purifying the enzyme to essential homogeneity.
- The screening for chemical characteristics may be effected on individual expression clones or may be initially effected on a mixture of expression clones to ascertain whether or not the mixture has one or more specified enzyme activities. If the mixture has a specified enzyme activity, then the individual clones may be rescreened for such enzyme activity or for a more specific activity. Thus, for example, if a clone mixture has hydrolase activity, then the individual clones may be recovered and screened to determine which of such clones has hydrolase activity.
- The present invention is also directed to preparing and providing enzyme kits for use in further screening and/or research. Thus, in accordance with an aspect of the invention, a reagent package or kit is prepared by placing in the kit or package, e.g., in suitable containers, at least three different recombinant enzymes with each of the at least three different recombinant enzymes having at least two enzyme characteristics in common. In a preferred embodiment, one common characteristic is a chemical characteristic or property and the other common characteristic is a physical characteristic or property: however, it is possible to prepare kits which have two or more chemical characteristics or properties in common and no physical characteristics or property in common and vice versa.
- Since, in accordance with the present invention, it is possible to provide a recombinant enzyme library from one or more microorganisms which is classified by a multiplicity of chemical and/or physical properties, a variety of enzyme kits or packages can be prepared having a variety of selected chemical and/or physical characteristics which can be formulated to contain three or more recombinant enzymes in which at least three and preferably all of the recombinant enzymes have in common at least one chemical characteristic and have in common at least one physical characteristic. The kit should contain an appropriate label specifying such common characteristics.
- In one embodiment, at least three recombinant enzymes in the kit have in common the most specific chemical characteristic specified on the label. The term “label” is used in its broadest sense and includes package inserts or literature associated or distributed in conjunction with the kit or package. Thus, for example, if the kit is labeled for a specific substrate (one of the
Tier 3 examples above), then for example, at least three of the enzymes in the kit would act on such substrate. - The kits will preferably contain more than three enzymes, for example, five, six or more enzymes and in a preferred embodiment at least three and preferably a majority and in some cases all of the recombinant enzymes in the kit will have at least two enzyme properties or characteristics in common, as hereinabove described.
- The recombinant enzymes in the kits may have two or more enzymes in a single container or individual enzymes in individual containers or various combinations thereof.
- The library may be screened for a specified enzyme activity by procedures known in the art. For example, the enzyme activity may be screened for one or more of the six IUB classes; oxidoreductases, transferases, hydrolases, lyases. isomerases and ligases. The recombinant enzymes which are determined to be positive for one or more of the IUB classes may then be rescreened for a more specific enzyme activity.
- Alternatively, the library may be screened for a more specialized enzyme activity. For example, instead of generically screening for hydrolase activity, the library may be screened for a more specialized activity, i.e. the type of bond on which the hydrolase acts. Thus, for example, the library may be screened to ascertain those hydrolases which act on one or more specified chemical functionalities, such as: (a) amide (peptide bonds), i.e. proteases: (b) ester bonds, i.e. esterases and lipases; (c) acetals, i.e., glycosidases etc.
- The clones which are identified as having the specified enzyme activity may then be sequenced to identify the DNA sequence encoding an enzyme having the specified activity. Thus, in accordance with the present invention it is possible to isolate and identify; (i) DNA encoding an enzyme having a specified enzyme activity, (ii) enzymes having such activity (inlcuding the amino acid sequence thereof) and (iii) produce recombinant enzymes having such activity.
- The screening for enzyme activity may be effected on individual expression clones or may be initially effected on a mixture of expression clones to ascertain whether or not the mixture has one or more specified enzyme activities. If the mixture has a specified enzyme activity, then the individual clones may be rescreened for such enzyme activity or for a more specific activity. Thus, for example, if a clone mixture has hydrolase activity, then the individual clones may be recovered and screened to determine which of such clones has hydrolase activity.
- The expression libraries may be screened for one or more selected chemical characteristics. Selected representative chemical characteristics are described below but such characteristics do not limit the present invention. Moreover, the expression libraries may be screened for some or all of the characteristics. Thus, some of the chemical characteristics specified herein may be determined in all of the libraries, none of the libraries or in only some of the libraries.
- The recombinant enzymes may also be tested and classified by physical properties. For example, the recombinant enzymes may be classified by physical properties such as follows:
- pH optima
- <3
- 3-6
- 6-9
- 9-12
- >12
- temperature optima
- >90° C.
- 75-90° C.
- 60-75° C.
- 45-60° C
- 30-45° C.
- 15-30° C.
- 0-15° C.
- temperature stability
- half-life at:
- 90° C.
- 75° C.
- 60° C.
- 45° C.
- organic solvent tolerance
- water miscible
- (DMF)
- 90%
- 75%
- 45%
- 30%
- water immiscible
- hexane
- toluene
- metal ion selectivity
- EDTA -10 mM
- Ca+2-1 mM
- Mg+2-100 μM
- Mn+2-10 μM
- Co+3-10 μM
- detergent sensitivity
- neutral (triton)
- anionic (deoxycholate)
- cationic (CHAPS)
- The recombinant enzymes of the libraries and kits of the present invention may be used for a variety of purposes and the present invention by providing a plurality of recombinant enzymes classified by a plurality of different enzyme characteristics permits rapid screening of enzymes for a variety of applications. Thus, for example, the present invention permits assembly of enzyme kits which contain a plurality of enzymes which are capable of operating on a specific bond or a specific substrate at specified conditions to thereby enable screening of enzymes for a variety of applications. As representative examples of such applications, there may be mentioned:
- 1. Lipase/Esterase
- a. Enantioselective hydrolysis of esters (lipids)/thioesters
- 1) Resolution of racemic mixtures
- 2) Synthesis of optically active acids or alcohols from meso-diesters
- b. Selective syntheses
- 1) Regiospecific hydrolysis of carbohydrate esters
- 2) Selective hydrolysis of cyclic secondary alcohols
- c. Synthesis of optically active esters, lactones, acids, alcohols
- 1) Transesterification of activated/nonactivated esters
- 2) Interesterification
- 3) Optically active lactones from hydroxyesters
- 4) Regio- and enantioselective ring opening of anhydrides
- d. Detergents
- e. Fat/Oil conversion
- f. Cheese ripening
- 2. Protease
- a. Ester/amide synthesis
- b. Peptide synthesis
- c. Resolution of racemic mixtures of amino acid esters
- d. Synthesis of non-natural amino acids
- e. Detergents/protein hydrolysis
- 3. Glycosidase/Glycosvl transferase
- a. Sugar/polymer synthesis
- b. Cleavage of glycosidic linkages to form mono, di-and oligosaccharides
- c. Synthesis of complex oligosaccharides
- d. Glycoside synthesis using UDP-galactosyl transferase
- e. Transglycosvlation of disaccharides, glycosyl fluorides, aryl galactosides
- f. Glycosyl transfer in oligosaccharide synthesis
- g. Diastereoselective cleavage of β-glucosylsulfoxides
- h. Asymmetric glycosylations
- i. Food processing
- j. Paper processing
- 4. Phosphatase/Kinase
- a. Synthesis/hydrolysis of phosphate esters
- 1) Regio-, enantioselective phosphorylation
- 2) Introduction of phosphate esters
- 3) Synthesize phospholipid precursors
- 4) Controlled polynucleotide synthesis
- b. Activate biological molecule
- c. Selective phosphate bond formation without protecting groups
- 5. Mono/Dioxygenase
- a. Direct oxyfunctionalization of unactivated organic substrates
- b. Hydroxylation of alkane, aromatics, steroids
- c. Epoxidation of alkenes
- d. Enantioselective sulphoxidation
- e. Regio- and stereoselective Bayer-Villiger oxidations
- 6. Haloperoxidase
- a. Oxidative addition of halide ion to nucleophilic sites
- b. Addition of hypohalous acids to olefinic bonds
- c. Ring cleavage of cyclopropanes
- d. Activated aromatic substrates converted to ortho and para derivatives
- e. 1.3 diketones converted to 2-halo-derivatives
- f. Heteroatom oxidation of sulfur and nitrogen containing substrates
- g. Oxidation of enol acetates, alkynes and activated aromatic rings
- 7. Lignin peroxidase/Diarvlpropane peroxidase
- a. Oxidative cleavage of C—C bonds
- b. Oxidation of benzylic alcohols to aldehvdes
- c. Hydroxylation of benzylic carbons
- d. Phenol dimerization
- e. Hydroxylation of double bonds to form diols
- f. Cleavage of lignin aldehydes
- 8. Epoxide hydrolase
- a. Synthesis of enantiomerically pure bioactive compounds
- b. Regio- and enantioselective hydrolysis of epoxide
- c. Aromatic and olefinic epoxidation by monooxygenases to form epoxides
- d. Resolution of racemic epoxides
- e. Hydrolysis of steroid epoxides
- 9. Nitrile hydratase/nitrilase
- a. Hydrolysis of aliphatic nitriles to carboxamides
- b. Hydrolysis of aromatic, heterocyclic, unsaturated aliphatic nitriles to corresponding acids
- c. Hydrolysis of acrylonitrile
- d. Production of aromatic and carboxamides, carboxylic acids (nicotinamide, picolinamide, isonicotinamide)
- e. Regioselective hydrolysis of acrylic dinitrile
- f. α-amino acids from α-hydroxynitriles
- 10. Transaminase
- a. Transfer of amino groups into oxo-acids
- 11. Amidase/Acylase
- a. Hydrolysis of amides, amidines, and other C—N bonds
- b. Non-natural amino acid resolution and synthesis
- The invention will be further described with reference to the following examples; however, the scope of the present invention is not to be limited thereby. Unless otherwise specified, all parts are by weight.
- The following describes a representative procedure for preparing an expression library for screening by the tiered approach of the present invention.
- One gram of Thermococcus GU5L5 cell pellet was lysed and the DNA isolated by literature procedures (Current Protocols in Molecular Biology, 2.4.1, 1987). Approximately 100μg of the isolated DNA was resuspended in TE buffer and vigorously passed through a 25 gauge double-hubbed needle until the sheared fragments were in the size range of 0.5-10.0 Kb (3.0 Kb average). The DNA ends were “polished” or blunted with Mung Bean Nuclease (300 units, 37° C., 15 minutes), and EcoRI restriction sites in the target DNA protected with EcoRI Methylase (200 units, 37° C., 1 hour). EcoRi linkers [GGAATTCC] were ligated to the blunted/protected DNA using 10 pmole ends of linkers to 1 pmole end of target DNA. The linkers were cut back with EcoRI restriction endonuclease (200 units, 37° C., 1.5 hours) and the DNA size fractionated by sucrose gradient (Maniatis, T., Fritsch, E. F., and Sambrook, J., Molecular Cloning. Cold Spring Harbor Press, New York, 1982). The prepared target DNA was ligated to the Lambda ZAP® II vector (Stratagene), packaged using in vitro lambda packaging extracts and grown on XL1-Blue MRF'E. coli strain according to the manufacturer. The pBluescript® phagemids were excised from the lambda library, and grown in E. coli DHIOB F' kan, according to the method of Hay and Short (Hav and Short. J. Strategies, 5:16, 1992). The resulting colonies were picked with sterile toothpicks and used to singly inoculate each of the wells of 11 96-well microtiter plates (1056 clones in all). The wells contained 250 μL of LB media with 100 μg/mL ampicillin. 80 μg/mL methicillin, and 10% v/v glycerol (LB Amp/Meth, glycerol). The cells were grown overnight at 37° C. without shaking. This constituted generation of the “Source Library”; each well of the Source Library thus contained a stock culture of E. coli cells, each of which contained a pBluescript phagemid with a unique DNA insert.
- The following outlines the procedures used to generate a gene library from a sample of the exterior surface of a whale bone found at 1240 meters depth in the Santa Catalina Basin during a dive expedition.
- Isolate DNA.
- IsoQuick Procedure as per manufacturer's instructions.
- Shear DNA
- 1. Vigorously push and pull DNA through a 25 G double-hub needle and 1-cc syringes about 500 times.
- 2. Check a small amount (0.5 μg) on a 0.8% agarose gel to make sure the majority of the DNA is in the desired size range (about 3-6 kb).
- Blunt DNA
- 1. Add:
H2O to a final volume of 405 μl 45 μl 10X Mung Bean Buffer 2.0 μl Mung Bean Nuclease (150 u/μl) - 2. Incubate 37° C., 15 minutes.
- 3. Phenol/chloroform extract once.
- 4. Chloroform extract once.
- 5. Add 1 ml ice cold ethanol to precipitate.
- 6. Place on ice for 10 minutes.
- 7. Spin in microfuge, high speed, 30 minutes.
- 8. Wash with 1 ml 70% ethanol.
- 9. Spin in microfuge, high speed, 10 minutes and dry.
- Methylate DNA
- 1. Gently resuspend DNA in 26 μl TE.
- 2. Add:
4.0 μl 10X EcoR I Methylase Buffer 0.5 μl SAM (32 mM) 5.0 μl EcoR I Methylase (40 u/μl) - 3. Incubate 37°, 1 hour.
- Insure Blunt Ends
- 1. Add to the methylation reaction:
5.0 μl 100 mM MgCl2 8.0 μl dNTP mix (2.5 mM of each dGTP, dATP, dTTP, dCTP) 4.0 μl Klenow (5 u/μl) - 2. Incubate 12° C., 30 minutes.
- 3. Add 450 μl IX STE.
- 4. Phenol/chloroform extract once.
- 5. Chloroform extract once.
- 6. Add 1 ml ice cold ethanol to precipitate and place on ice for 10 minutes.
- 7. Spin in microfuge, high speed. 30 minutes.
- 8. Wash with 1 ml 70% ethanol.
- 9. Spin in microfuge, high speed, 10 minutes and dry.
- Linker Ligation
- 1. Gently resuspend DNA in 7 μl Tris-EDTA (TE).
- 2. Add:
14 μl Phosphorylated EcoR I linkers (200 ng/μl) 3.0 μl 10X Ligation Buffer 3.0 μl 10 mM rATP 3.0 μl T4 DNA Ligase (4 Wu/μl) - 3.
Incubate 4° C., overnight. - EcoRI Cutback
- 1. Heat kill ligation reaction 68° C. 10 minutes.
- 2. Add:
237.9 μl H2O 30 μl 10X EcoR I Buffer 2.1 μl EcoR I Restriction Enzyme (100 u/μl) - 3. Incubate 37° C., 1.5 hours.
- 4. Add 1.5 μl 0.5 M EDTA.
- 5. Place on ice.
- Sucrose Gradient (2.2 ml) Size Fractionation
- 1. Heat sample to 65° C., 10 minutes.
- 2. Gently load on 2.2 ml sucrose gradient.
- 3. Spin in mini-ultracentrifuge, 45 K. 20° C. 4 hours (no brake).
- 4. Collect fractions by puncturing the bottom of the gradient tube with a 20 G needle and allowing the sucrose to flow through the needle. Collect the first 20 drops in a Falcon 2059 tube then collect 10 1-drop fractions (labelled 1-10). Each drop is about 60 μl in volume.
- 5. Run 5 μl of each fraction on a 0.8% agarose gel to check the size.
- 6. Pool fractions 1-4 (-10-1.5 kb) and, in a separate tube, pool fractions 5-7 (about 5-0.5 kb).
- 7. Add 1 ml ice cold ethanol to precipitate and place on ice for 10 minutes.
- 8. Spin in microfuge, high speed, 30 minutes.
- 9. Wash with 1 ml 70% ethanol.
- 10. Spin in microfuge, high speed, 10 minutes and dry.
- 11. Resuspend each in 10 μl TE buffer.
- Test Ligation to Lambda Arms
- 1. Plate assay to get an approximate concentration. Spot 0.5 μl of the sample on agarose containing ethidium bromide along with standards (DNA samples of known concentration). View in UV light and estimate concentration compared to the standards. Fraction 1-4=>1.0 μg/μl. Fraction 5-7=500 μg/μl. 2. Prepare the following ligation reactions (5 μl reactions) and incubate 4° C. overnight:
Lambda 10X arms T4 DNA Ligase 10 mM (gt11 and Insert Ligase (4 Sample H2O Buffer rATP ZAP) DNA Wu/μ) Fraction 1-4 0.5 μl 0.5 μl 0.5 μl 1.0 μl 2.0 μl 0.5 μl Fraction 5-7 0.5 μl 0.5 μl 0.5 μl 1.0 μl 2.0 μl 0.5 μl - Test Package and Plate
- 1. Package the ligation reactions following manufacturer's protocol. Package 2.5 μl per packaging extract (2 extracts per ligation).
- 2. Stop packaging reactions with 500 μl SM buffer and pool packaging that came from the same ligation.
- 3 Titer 1.0 μl of each on appropriate host (OD600=1.0) [XLI-Blue MRF for ZAP and Y1088 for gt11]
- Add 200 μl host (in mM MgSO4) to Falcon 2059 tubes
- Inoculate with 1 μl packaged phage
- Incubate 37° C., 15 minutes
- Add about 3 ml 48° C. top agar
- [50 ml stock containing 150 μl IPTG (0.5 M) and 300 μl X-GAL (350 mg/ml)]
- Plate on 100 mm plates and incubate 37° C., overnight.
- 4. Efficiency results:
- gt 11. 1.7×104 recombinants with 95% background
- ZAP 11:4.2×104 recombinants with 66% background
- Contaminants in the DNA sample may have inhibited the enzymatic reactions, though the sucrose gradient and organic extractions may have removed them. Since the DNA sample was precious, an effort was made to “fix” the ends for cloning:
- Re-Blunt DNA
- 1. Pool all left over DNA that was not ligated to the lambda arms (Fractions 1-7) and add H2O to a final volume of 12 μl. Then add:
143 μl H2O 20 μl 10X Buffer 2 (from Stratagene's cDNA Synthesis Kit) 23 μl Blunting dNTP (from Stratagene's cDNA Synthesis Kit) 2.0 μl Pfu (from Stratagene″s cDNA Synthesis - 2. Incubate 72° C., 30 minutes.
- 3. Phenol/chloroform extract once.
- 4. Chloroform extract once.
- 5. Add 20 μL 3 M NaOAc and 400 μl ice cold ethanol to precipitate.
- 6. Place at −20° C., overnight.
- 7. Spin in microfuge, high speed, 30 minutes.
- 8. Wash with 1 ml 70% ethanol.
- 9. Spin in microfuge, high speed, 10 minutes and dry.
- (Do NOT Methylate DNA Since it was Already Methylated in the First Round of Processing)
- Adaptor Ligation
- 1. Gently resuspend DNA in 8 μl EcoR I adaptors (from Stratagene's cDNA Synthesis Kit).
- 2. Add:
1.0 μl 10X Ligation Buffer 1.0 μl 10 mM rATP 1.0 μl T4 DNA Ligase (4 Wu/μl) - 3.
Incubate 4° C. 2 days. - (Do NOT Cutback Since Using ADAPTORS This Time. Instead, Need to Phosphervlate)
- Phosphorvlate Adaptors
- 1. Heat kill ligation reaction 70° C. 30 minutes. Add:
1.0 μl 10X Ligation Buffer 2.0 μl 10 mM rATF 6.0 μl H2O 1.0 μl PNK (from Stratagene's cDNA Synthesis Kit). - Kit).
- 3. Incubate 37° C., 30 minutes.
- 4. Add 31 μl H2O and 5
μl 10×STE. - 5. Size fractionate on a Sephacryl S-500 spin column (pool fractions 1-3).
- 6. Phenol/chloroforrn extract once.
- 7. Chloroform extract once.
- 8. Add ice cold ethanol to precipitate.
- 9. Place on ice, 10 minutes.
- 10. Spin in microfuge, high speed, 30 minutes.
- 11. Wash with 1 ml 70% ethanol.
- 12. Spin in microfuge, high speed. 10 minutes and dry.
- 13. Resuspend in 10.5 μl TE buffer.
- Do Not Plate Assay. INSTEAD, Ligate directly to Arms as Above Except Use 2.5 μl of DNA and No Water.
- Package and Titer as Above.
- Efficiency results:
gt11: 2.5 × 106 recombinants with 2.5% background ZAP II: 9.6 × 105 recombinants with 0% background - Amplification of Libraries (5.0×105 Recombinants From Each Library)
- 1. Add 3.0 ml host cells (OD600=1.0) to two 50 ml conical tube.
- 2. Inoculate with 2.5×105 pfu per conical tube.
- 3. Incubate 37° C., 20 minutes.
- 4. Add top agar to each tube to a final volume of 45 ml.
- 5. Plate the tube across five 150 mm plates.
- 6. Incubate 37° C., 6-8 hours or until plaques are about pin-head in size.
- 7. Overlay with 8-10 ml SM Buffer and place at 4° C. overnight (with gentle rocking if possible).
- Harvest Phage
- 1. Recover phage suspension by pouring the SM buffer off each plate into a 50-ml conical tube.
- 2. Add 3 ml chloroform, shake vigorously and incubate at room temperature, 15 minutes.
- 3. Centrifuge at 2K rpm, 10 minutes to remove cell debris.
- 4. Pour supernatant into a sterile flask, add 500 μl chloroform.
- 5. Store at 4° C.
- Titer Amplified Library
- 1. Make serial dilutions:
- 10−5=1 μl amplified phage in 1 ml SM Buffer
- 10−6=1 μl of the 10−3 dilution in 1 ml SM Buffer
- 2. Add 200 μl host (in 10 mM MgSO4) to two tubes.
- 3. Inoculate one with 10
μl 10−6 dilution (10−5). - 4. Inoculate the other with 1
μl 10−6 dilution (10-6). - 5. Incubate 37° C., 15 minutes.
- 6. Add about 3 ml 48° C. top agar.
- [50 ml stock containing 150 μl IPTG (0.5M) and 375 μl X-GAL (350 mg/ml)]
- 7. Plate on 100 mm plates and incubate 37° C., overnight.
- 8. Results:
gt11: 1.7 × 1011/ml ZAP II: 2.0 × 1010/ml - Excise The ZAP II Library to Create The pBluescript library.
- FIG. 1 shows an overview of the procedures used to construct an environmental library from a mixed picoplankton sample. The goal was to construct a stable, large insert DNA library representing picoplankton genomic DNA.
- Cell Collection and Preparation of DNA.
- Agarose plugs containing concentrated picoplankton cells were prepared from samples collected on an oceanographic cruise from Newport, Oregon to Honolulu. Hi. Seawater (30 liters) was collected in Niskin bottles, screened through 10 Am Nitex, and concentrated by hollow fiber filtration (Amicon DC10) through 30,000 MW cutoff polysulfone filters. The concentrated bacterioplankton cells were collected on a 0.22 μm, 47 mm Durapore filter, and resuspended in 1 ml of 2×STE buffer (1M NaCl, 0. IM EDTA, 10 mM Tris, pH 8.0) to a final density of approximately 1×1010 cells per ml. The cell suspension was mixed with one volume of 1% molten Seaplaque LMP agarose (FMC) cooled to 40° C., and then immediately drawn into a 1 ml syringe. The syringe was sealed with parafilm and placed on ice for 10 min. The cell-containing agarose plug was extruded into 10 ml of Lysis Buffer (10 mM Tris pH 8.0, 50 mM NaCl, 0.1 M EDTA, 1% Sarkosyl, 0.2% sodium deoxycholate, a mg/ml lysozyme) and incubated at 37° C. for one hour. The agarose plug was then transferred to 40 mis of ESP Buffer (1% Sarkosyl, 1 mg/ml proteinase-K, in 0.5M EDTA), and incubated at 55° C. for 16 hours. The solution was decanted and replaced with fresh ESP Buffer, and incubated at 55° C. for an additional hour. The agarose plugs were then placed in 50 mM EDTA and stored at 4° C. shipboard for the duration of the oceanographic cruise.
- One slice of an agarose plug (72 μl) prepared from a sample collected off the Oregon coast was dialyzed overnight at 4° C. against 1 mL of buffer A (100 mM NaCl, 10 mM Bis Tris Propane-HCl, 100 μg/ml acetylated BSA: pH 7.0 @ 25° C.) in a 2 mL microcentrifuge tube. The solution was replaced with 250 μl of fresh buffer A containing 10 mM MgCl2 and 1 mM DTT and incubated on a rocking platform for 1 hr at room temperature. The solution was then changed to 250 μl of the same buffer containing 4 U of Sau3AI (NEB), equilibrated to 37° C. in a water bath, and then incubated on a rocking platform in a 37° C. incubator for 45 min. The plug was transferred to a 1.5 ml microcentrifuge tube and incubated at 68° C. for 30 min to inactivate the protein, e.g. enzyme, and to melt the agarose. The agarose was digested and the DNA dephosphorylased using Gelase and HK-phosphatase (Epicentre), respectively according to the manufacturer s recommendations. Protein was removed by gentle phenol/chloroform extraction and the DNA was ethanol precipitated, pelleted, and then washed with 70% ethanol. This partially digested DNA was resuspended in sterile H2O to a concentration of 2.5 ng/μl for ligation to the pFOSI vector.
- PCR amplification results from several of the agarose plugs (data not shown) indicated the presence of significant amounts of archaeal DNA. Quantitative hybridization experiments using rRNA extracted from one sample, collected at 200 m of depth off the Oregon Coast, indicated that planktonic archaea in (this assemblage comprised approximately 4.7% of the total picoplankton biomass (this sample corresponds to “PACI ”-200 m in Table 1 of DeLong et al., high abundance of Archaea in Antarctic marine picoplankton, Nature, 371:695-698, 1994). Results from archaeal-biased rDNA PCR amplification performed on agarose plug lysates confirmed the presence of relatively large amounts of archaeal DNA in this sample. Agarose plugs prepared from this picoplankton sample were chosen for subsequent fosmid library preparation. Each 1 ml agarose plug from this site contained approximately 7.5×105 cells, therefore approximately 5.4×105 cells were present in the 72 μl slice used in the preparation of the partially digested DNA.
- Vector arms were prepared from pFOSI as described (Kim et al. Stable propagation of casmid sized human DNA inserts in an F factor based vector. Nucl. Acids Res., 20:10832-10835. 1992). Briefly, the plasmid was completely digested with AstII, dephosphorylated with HK phosphatase, and then digested with BamHI to generate two arms, each of which contained a cos site in the proper orientation for cloning and packaging ligated DNA between 3545 kbp. The partially digested picoplankton DNA was ligated overnight to the PFOS1 arms in a 15 μl ligation reaction containing 25 ng each of vector and insert and 1 U of T4 DNA ligase (Boehringer-Mannheim). The ligated DNA in four microliters of this reaction was ill vitro packaged using the Gigapack XL packaging system (Stratagene), the fosmid particles transfected toE. coli strain DHIOB (BRL), and the cells spread onto LBcm15 plates. The resultant fosmid clones were picked into 96-well microliter dishes containing LBcm15 supplemented with 7% glycerol. Recombinant fosmids, each containing ca. 40 kb of picoplankton DNA insert, yielded a library of 3.552 fosmid clones, containing approximately 1.4×108 base pairs of cloned DNA. All of the clones examined contained inserts ranging from 38 to 42 kbp. This library was stored frozen at −80° C. for later analysis.
- The following is a representative example of a procedure for screening an expression library prepared in accordance with Example 2. In the following, the chemical characteristic Tiers are as follows:
- Tier 1: Hydrolase
- Tier 2: Amide. Ester and Acetal
- Tier 3: Divisions and subdivisions are based upon the differences between individual substrates which are covalently attached to the functionality of
Tier 2 undergoing reaction; as well as substrate specificity. - Tier 4: The two possible enantiomeric products which the enzyme may produce from a substrates
- Although the following example is specifically directed to the above mentioned tiers, the general procedures for testing for various chemical characteristics is generally applicable to substrates other than those specifically referred to in this Example.
- Screening for Tier 1-hydrolase: Tier 2-amide.
- The eleven plates of the Source Library were used to multiply inoculate a single plate (the “Condensed Plate”) containing in each well 200 μL of LB Amp/Meth, glycerol. This step was performed using the High Density Replicating Tool (HDRT) of the Beckman Biomek with a 1% bleach water, isopropanol, air-dry sterilization cycle in between each inoculation. Each well of the Condensed Plate thus contained 11 different pBluescript clones from each of the eleven source library plates. The Condensed Plate was grown for 2h at 37° C. and then used to inoculate two white 96-well Dynatech microtiter daughter plates containing in each well 250 μL of LB Amp/Meth, glycerol. The original condensed plates was incubated at 37° C. for 18 h then stored at −80° C. The two condensed daughter plates were incubated at 37° C. also for 18 h. The condensed daughter plates were then heated at 70° C. for 45 min. to kill the cells and inactivate the hostE. coli enzymes. A stock solution of 5 mg/mL morphourea phenylalanyl-7-amino-4-trifluoromethyl coumarin (MuPheAFC, the ‘substrate’) in DMSO was diluted to 600 AM with 50 mM pH 7.5 Hepes buffer containing 0.6 mg/mL of the detergent dodecyl maltoside.
- Fifty μL of the 600 μM MuPheAFC solution was added to each of the wells of the white condensed plates with one 100 μL mix cycle using the Biomek to yield a final concentration of substrate of˜100 μM. The fluorescence values were recorded (excitation =400 nm, emission=505 nm) on a plate reading fluorometer immediately after addition of the substrate (t=0). The plate was incubated at 70° C. for 100 min, then allowed to cool to ambient temperature for 15 additional minutes. The fluorescence values were recorded again (t=100). The values at t=0 were subtracted from the values at t=100 to determine if an active clone was present.
- These data indicated that one of the eleven clones in well G8 was hydrolyzing the substrate. In order to determine the individual clone which carried the activity, the eleven source library plates were thawed and the individual clones used to singly inoculate a new plate containing LB Amp/Meth, glycerol. As above, the plate was incubated at 37° C. to grow the cells, heated at 70° C. to inactivate the host enzymes, and 50 μL of 600 μM MuPheAFC added using the Biomek. Additionally three other substrates were tested. The methyl umbelliferone heptanoate, the CBZ-arginine rhodamine derivative, and fluorescein-conjugated casein (˜3.2 mol fluorescein per mol of casein).
- The umbelliferone and rhodamine were added as 600 μM stock solutions in 50 μL of Hepes buffer. The fluorescein conjugated casein was also added in 50 μL at a stock concentration of 20 and 200 mg/mL. After addition of the substrates the t=0 fluorescence values were recorded, the plate incubated at 70° C., and the t =100 min, values recorded as above.
- These data indicated that the active clone was in plate
- 2. The arginine rhodamine derivative was also turned over by this activity, but the lipase substrate, methyl umbelliferone heptanoate, and protein, fluorescein-conjugated casein, did not function as substrates.
- Based on the above data the
Tier 1 classification is ‘hydrolase’ and theTier 2 classification is amide bond. There is no cross reactivity with the Tier 2-ester classification. - As shown in FIG. 2, a recombinant clone from the library which has been characterized in
Tier 1 as hydrolase and inTier 2 as amide may then be tested inTier 3 for various specificities. In FIG. 2, the various classes ofTier 3 are followed by a parenthetical code which identifies the substrates of Table 1 which are used in identifying such specificities ofTier 3. - As shown in FIGS. 3 and 4, a recombinant clone from the library which has been characterized in
Tier 1 as hydrolase and inTier 2 as ester may then be tested inTier 3 for various specificities. In FIGS. 3 and 4, the various classes ofTier 3 are followed by a parenthetical code which identifies the substrates of Tables 2 and 2 which are used in identifying such specificities ofTier 3. In FIGS. 3 and 4, R2 represents the alcohol portion of the ester and R1 represents the acid portion of the ester. - As shown in FIG. 5, a recombinant clone from the library which has been characterized in
Tier 1 as hydrolase and inTier 2 as acetal may then be tested inTier 3 for various specificities. In FIG. 5, the various classes ofTier 3 are followed by a parenthetical code which identifies the substrates of Table 4 which are used in identifying such specificities ofTier 3. -
-
- where eeP=the enantiomeric excess (ee) of the hydrolyzed product and c=the percent conversion of the reaction. See Wong and Whitesides. Enzymes in Synthetic Organic Chemistry, 1994, Elsevier, Tarrytown, N.Y., pgs. 9-12.
- The enantiomeric excess is determined by either chiral high performance liquid chromatography (HPLC) or chiral capillary electrophoresis (CE). Assays are performed as follows: two hundred μL of the appropriate buffer is added to each well of a 96-well white microtiter plate, followed by 50 μL of partially or completely purified enzyme solution, 50 μL of substrate is added and the increase in fluorescence monitored versus time until 50% of the substrate is consumed or the reaction stops, which ever comes first.
- Enantioselectivity was determined for one of the esterases identified as follows. For the reaction to form (transesterification) or breakdown (hydrolysis) α-methyl benzyl acetate, the enantioselectivity of the enzyme was obtained by determining: eeC (the enantiomeric excess (ee) of the unreacted substrate), eeP (the ee of the hydrolyzed product), and c (the percent conversion of the reaction). The enantiomeric excess was by determined chiral high performance gas chromatography (GC). Chromatography conditions were as follows:
- Sample Preparation: Samples were filtered through a 0.2 μm, 13 mm diameter PTFE filter.
- Column: Supelco β-DEX 120, 0.25 mm ID. 30 m, 0.25 Am df.
- Oven: 90° C. for 1 min, then 90° C. to 150° C at 5° C./min.
- Carrier Gas: Helium, 1 mL/min for 2 min then 1 mL/min, to 3 mL/min at 0.2 mL/min.
- Detector: FID, 300° C.
- Injection: 1 μL (1 mM substrate in reaction solvent), split (1:75), 200° C.
- The transesterification reaction was performed according to the procedure described in: Organic solvent tolerance. Water immiscible solvents. See below.
- Transesterification with Enzyme ESL-001-01 gave the following results:
Solvent % ees % eep % c n-heptane 10.9 44.3 19.8 toluene 3.2 100 3.1 - The hydrolysis reaction was performed as follows: Fifty μL of a 10 mM solution of α-methyl benzyl acetate in 10% aqueous DMSO (v/v) was added to 200 μL of 100 mM, pH 6.9 phosphate buffer. To this solution was added 250 AL of Enzyme ESL-001-01(2 mg/mL in 100 mM, pH 6.9 phosphate buffer) and the reaction heated at 70° C. for 15 min. The reaction was worked up according to the following procedure: remove 250 μL of hydrolysis reaction mixture and add to a 1 mL Eppendorf tube. Add 250 AL of ethyl acetate and shake vigorously for 30 seconds. Allow phases to separate for 15 minutes. Pipette off 200 μL of top organic phase and filter through a 0.2 μm. 4 mm diameter PTFE filter. Analyze by chiral GC as above.
- Hydrolysis with Enzvme ESL-001-01 gave the following results:
% ees % eep % c 100 0.7 99.3 - This example describes procedures for testing for certain physical characteristics of a recombinant clone of a library.
- pH Optima.
- Two hundred μL of 4-methy 1-umbelliferyl-2 ,2-dimethyl-4-pentenoate was added to each well of a 96-well microtiter plate and serially diluted from
column 1 to 12. Fifty μL of the appropriate 5×pH buffer was added to each row of the plate so that reaction rate in eight different pH's were tested on a single plate. Twenty μL of Enzyme ESL-001-01 (1:3000 dilution of a 1 mg/mL stock solution) was added to each well to initiate the reaction. The increase in absorbance at 370 nm at 70° C. was monitored to determine the rate of reaction; the rate versus substrate concentration fit to the Michaelis-Menten equation to determine VMAX at each pH. - Enzyme ESL-001-01 gave the results shown in FIG. 6.
- Temperature Optima.
- To a one mL thermostatted cuvette was added 930 μL of 50 mM, pH 7.5 Hepes buffer. After temperature equilibration 50 AL of Enzyme ESL-001-01 (1:8000 dilution of a 1 mg/mL stock solution in Hepes buffer) and 20 μL of 5 mM 4-methyl-umbelliferyl-heptanoate containing 30 mg/mL dodecyl maltoside. The rate of increase in absorbance at 370 nm was measured at 10, 20, 30, 40, 50, 60, 70, 80,and 90° C.
- Enzyme ESL-001-01 Gave the Results Shown in FIG. 7. ability.
- Temperature Stability.
- One mL samples of Enzyme ESL-001-01 (1:4000 dilution of a 1 mg/mL stock solutions in Hepes buffer) were incubated at 70, 80, and 90° C. At selected time points 25 μL aliquots were removed and assayed as above in a 96 well microtiter plate with 200 μL of 100 μM 4-methylumbelliferyl palmitate and 0.6 mg/mL dodecyl maltoside. This data was used to determine the half life for inactivation of the enzyme.
- Enzyme ESL-001-01 gave the following results:
Temperature Half Life 90 23 min. 80 32 min. 70 110 h - Organic Solvent Tolerance.
- Water Miscible Solvents (Dimethylsulfoxide (DMSO) and Tetrahydro Furan (THF)).
- Thirty μL of of 1 mM 4-methyl-umbelliferyl-butyrate in the organic solvent was added to the wells of a 96-well miciotiter plate. Two hundred forty μL of buffer and organic solvent mixture (see table below) were added the wells of the plate, followed by 30 μL of an Enzyme ESL-001-01 (1:50,000 dilution of a 1 mg/mL stock solution in 50 mM, pH 6.9 MOPS buffer) and incubation at 70° C. The increase in fluorescence (EX=360 nm, EM=440 nm) was monitored versus time to determine the relative activities.
μL Organic Solvent μL Buffer % Organic Solvent Final 240 0 90 195 45 75 150 90 60 120 120 50 90 150 40 60 180 30 30 210 20 0 240 10 - Enzyme ESL-001-01 Ol gave the results shown in FIG. 8.
- Water Immiscible Solvents (n-heptane, toluene)
- One mL of the solvent was added to a vial containing 1 mg of lyophilized Enzyme ESL-001-01 and a stir bar. Ten μL of 100 mM 1-phenethyl alcohol and 10 μL of 100 mM vinyl acetate were added to the vial and the vial stirred in a heating block at 70° C. for 24 h. The sample was filtered through a 0.2 μm. 4 mm diameter PTFE filter and analyzed by chiral GC as above. See previous section for data.
- Specific Activity
- The specific activity was determined using 100 μM 4-methyl umbelliferyl heptanoate at 90° C. in pH 6.9 MOPS buffer. The specific activity obtained for Enzyme ESL-001-01 was 1662 μmol/min mg.
- This example describes procedures for testing for substrate specificity of a recombinant clone of a library.
- Substrate Fingerprint.
- One and one quarter millimolar solutions containing 1 mg/mL of dodecyl maltoside in 50 mM pH 6.9 MOPS buffer of each of the following substrates were prepared:
- 4-methyl umbelliferyl acetate (A)
- 4-methyl umbelliferyl propanoate (B)
- 4-methyl umbelliferyl butyrate (C)
- 4-methyl umbelliferyl heptanoate (D)
- 4-methyl umbelliferyl α-methyl butyrate (E)
- 4-methyl umbelliferyl β-methylcrotonoate (F)
- 4-
methyl umbelliferyl 2,2-dimethyl-4-pentenoate (G) - 4-methyl umbelliferyl adipic acid monoester (H)
- 4-
methyl umbelliferyl 1,4-cycylohexane dicarboxylate (1) - 4-methyl umbelliferyl benzoate (M)
- 4-methyl umbelliferyl p-trimethyl ammonium cinnamate (N)
- 4-methyl umbelliferyl 4-guanidinobenzoate (0)
- 4-methyl umbelliferyl α-methyl phenyl acetate (P)
- 4-methyl umbelliferyl α-methoxy phenyl acetate (Q)
- 4-methyl umbelliferyl palmitate (S)
- 4-methyl umbelliferyl stearate (T)
- 4-methyl umbelliferyl oleate (U)
- 4-methyl umbelliferyl elaidate (W).
- Two hundred μL of each of the above solutions were added to the wells of a 96 well microtiter plate, followed by 50 μL of Enzyme ESL-001-01 (1:2000 dilution of a 1 mg/mL stock solution in MOPS buffer) and incubation at 70° C. for 20 min. The fluorescence (EX=360 nm, EM=440 nm) was measured and fluorescence due to nonenzymatic hydrolysis was subtracted. Table 5 shows the relative fluorescence of each of the above substrates.
- Numerous modifications and variations of the present invention are possible in light of the above teachings: therefore, within the scope of the claims, the invention may be practiced other than as particularly described.
TABLE 1 A2 Fluorescein conjugated casein (32 mol fluorescein/mol casein) CBZ-Ala-AMC t-BOC-Ala-Ala-Asp-AMC succinyl-Ala-Gly-Leu-AMC CBZ-Arg-AMC CBZ-Met-AMC morphourea-Phe-AMC t-BOC = t-butoxy carbonyl, CBZ = carbonyl benzyloxy. AMC = 7-amino-4-methyl coumarin AD3 Fluorescein conjugated casein t-BOC-Ala-Ala-Asp-AFC CBZ-Ala-Ala-Lys-AFC succinyl-Ala-Ala-Phe-AFC succinyl-Ala-Gly-Leu-AFC AFC = 7-amino-4-trifluoromethyl coumarin.) AE3 Fluorescein conjugated casein AF3 t-BOC-Ala-Ala-Asp-AFC CBZ-Asp-AFC AG3 CBZ Ala-Ala-Lys-AFC CBZ-Arg-AFC AH3 succinyl-Ala-Ala-Phe-AFC CBZ-Phe-AFC CBZ-Trp-AFC AI3 succinyl-Ala Gly Leu-AFC CBZ-Ala-AFC CBZ-Sewr-AFC -
-
-
TABLE 4 wherein R = 4-methyl umbelliferone G2 β-D-galactose β-D-glucose β-D-glucoronide GB3 β-D-cellotrioside β-B-cellobiopyranoside GC3 β-D-galactose α-D-galactose GD3 β-D-glucose α-D-glucose GE3 β-D-glucoronide GI3 β-D-N,N-diacetylchitobiose GJ3 β-D-fucose α-L-fucose β-L-fucose GK3 β-D-mannose α-D-mannose non-Umbelliferyl substrates GA3 amylose [polyglucan α1,4 linkages], amylopectin [polyglucan branching α1,6 linkages] GF3 xylan [ poly 1,4-D-xylan]GG3 amylopectin, pullulan GH3 sucrose, fructofuranoside -
TABLE 5 RELATIVE COMPOUND FLUORESCENCE A 60.6 B 73.6 C 100.0 D 84.3 E 29.1 F 5.4 G 7.1 H 0.9 I 0.0 M 9.4 N 0.5 O 0.5 P 4.0 Q 11.3 S 0.6 T 0.1 U 0.3 W 0.2
Claims (3)
1. A process for identifying clones of a recombinant library produced from DNA derived from at least one uncultivated organism which express a protein with a desired characteristic, comprising:
screening in the liquid phase a library of expression clones randomly produced from DNA of at least one uncultivated organism, said screening being effected on expression products of said clones to thereby identify clones which express a protein with a desired characteristic.
2. The method of claim 1 , wherein the DNA is optionally modified or mutagenized prior to formation of the recombinant library.
3. A process of screening clones having DNA recovered from an uncultivated organism for a specified protein characteristic, which process comprises:
screening for a specified protein characteristic in a library of clones prepared by
(i) recovering DNA from a DNA population derived from at least one uncultivated organism; and
(ii) transforming a host cell with the recovered DNA to produce a library of clones which is screened for the specified protein characteristic, wherein the DNA is optionally modified or mutagenized prior to forming a library of clones.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/753,752 US20020058254A1 (en) | 1995-07-18 | 2001-01-02 | Screening methods for enzymes and enzyme kits |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/503,606 US6004788A (en) | 1995-07-18 | 1995-07-18 | Enzyme kits and libraries |
US56899495A | 1995-12-07 | 1995-12-07 | |
US08/657,409 US5958672A (en) | 1995-07-18 | 1996-06-03 | Protein activity screening of clones having DNA from uncultivated microorganisms |
US08/983,367 US6168919B1 (en) | 1996-07-17 | 1996-07-17 | Screening methods for enzymes and enzyme kits |
PCT/US1996/011854 WO1997004077A1 (en) | 1995-07-18 | 1996-07-17 | Screening methods for enzymes and enzyme kits |
USPCT/US96/11854 | 1996-07-17 | ||
US09/753,752 US20020058254A1 (en) | 1995-07-18 | 2001-01-02 | Screening methods for enzymes and enzyme kits |
Related Parent Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/503,606 Division US6004788A (en) | 1995-07-18 | 1995-07-18 | Enzyme kits and libraries |
US56899495A Division | 1995-07-18 | 1995-12-07 | |
US08/657,409 Division US5958672A (en) | 1995-07-18 | 1996-06-03 | Protein activity screening of clones having DNA from uncultivated microorganisms |
US08/983,367 Division US6168919B1 (en) | 1995-07-18 | 1996-07-17 | Screening methods for enzymes and enzyme kits |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020058254A1 true US20020058254A1 (en) | 2002-05-16 |
Family
ID=25529916
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/983,367 Expired - Lifetime US6168919B1 (en) | 1995-07-18 | 1996-07-17 | Screening methods for enzymes and enzyme kits |
US09/753,752 Abandoned US20020058254A1 (en) | 1995-07-18 | 2001-01-02 | Screening methods for enzymes and enzyme kits |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/983,367 Expired - Lifetime US6168919B1 (en) | 1995-07-18 | 1996-07-17 | Screening methods for enzymes and enzyme kits |
Country Status (1)
Country | Link |
---|---|
US (2) | US6168919B1 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US6995017B1 (en) | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6165793A (en) * | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US7018793B1 (en) * | 1995-12-07 | 2006-03-28 | Diversa Corporation | Combinatorial screening of mixed populations of organisms |
US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US20070009930A1 (en) * | 1996-12-18 | 2007-01-11 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
CA2276064C (en) | 1997-01-17 | 2013-12-17 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
US7148054B2 (en) | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
US6159688A (en) | 1997-03-18 | 2000-12-12 | Novo Nordisk A/S | Methods of producing polynucleotide variants |
EP1036198B1 (en) | 1997-12-08 | 2012-09-26 | California Institute Of Technology | Method for creating polynucleotide and polypeptide sequences |
US6541011B2 (en) | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
US7390619B1 (en) * | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
NZ507591A (en) | 1998-05-01 | 2002-03-28 | Maxygen Inc | Optimization of pest resistance genes using DNA shuffling |
US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
US20040005673A1 (en) * | 2001-06-29 | 2004-01-08 | Kevin Jarrell | System for manipulating nucleic acids |
ATE439437T1 (en) * | 1999-01-05 | 2009-08-15 | Univ Boston | IMPROVED CLONING PROCESS |
JP3399518B2 (en) * | 1999-03-03 | 2003-04-21 | インターナショナル・ビジネス・マシーンズ・コーポレーション | Semiconductor structure and method of manufacturing the same |
AU3391900A (en) | 1999-03-05 | 2000-09-21 | Maxygen, Inc. | Encryption of traits using split gene sequences |
US20040002474A1 (en) * | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
US7115712B1 (en) * | 1999-12-02 | 2006-10-03 | Maxygen, Inc. | Cytokine polypeptides |
WO2001051663A2 (en) * | 2000-01-11 | 2001-07-19 | Maxygen, Inc. | Integrated systems and methods for diversity generation and screening |
AU2001241939A1 (en) * | 2000-02-28 | 2001-09-12 | Maxygen, Inc. | Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation |
EP1276861A2 (en) * | 2000-03-24 | 2003-01-22 | Maxygen, Inc. | Methods for modulating cellular and organismal phenotypes |
AU2001268716A1 (en) * | 2000-06-23 | 2002-01-08 | Maxygen, Inc. | Novel chimeric promoters |
US7094875B2 (en) * | 2000-06-23 | 2006-08-22 | Maxygen, Inc. | Co-stimulatory polypeptides |
WO2002004629A2 (en) * | 2000-07-07 | 2002-01-17 | Maxygen, Inc. | Molecular breeding of transposable elements |
US6858422B2 (en) * | 2000-07-13 | 2005-02-22 | Codexis, Inc. | Lipase genes |
EP1317535A2 (en) * | 2000-08-24 | 2003-06-11 | Maxygen, Inc. | Constructs and their use in metabolic pathway engineering |
CA2456229A1 (en) * | 2001-08-03 | 2003-02-13 | Diversa Corporation | Epoxide hydrolases, nucleic acids encoding them and methods for making and using them |
WO2003072054A2 (en) * | 2002-02-25 | 2003-09-04 | Cabot Corporation | Custom ligand design for biomolecular filtration and purification for bioseperation |
ES2335232T3 (en) | 2005-06-21 | 2010-03-23 | Xoma Technology Ltd. | ANTIBODIES AND FRAGMENTS OF THE SAME THAT JOIN THE IL-1 BETA. |
US20070119572A1 (en) * | 2005-11-30 | 2007-05-31 | Raytheon Company | System and Method for Boiling Heat Transfer Using Self-Induced Coolant Transport and Impingements |
TWI369402B (en) | 2006-07-05 | 2012-08-01 | Catalyst Biosciences Inc | Protease screening methods and proteases identified thereby |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5171684A (en) * | 1988-04-05 | 1992-12-15 | Amgen Inc. | Bioconversions catalyzed by the toluene monooxygenase of Pseudomanas mendocina KR-1 |
US5712146A (en) * | 1993-09-20 | 1998-01-27 | The Leland Stanford Junior University | Recombinant combinatorial genetic library for the production of novel polyketides |
US5958672A (en) * | 1995-07-18 | 1999-09-28 | Diversa Corporation | Protein activity screening of clones having DNA from uncultivated microorganisms |
-
1996
- 1996-07-17 US US08/983,367 patent/US6168919B1/en not_active Expired - Lifetime
-
2001
- 2001-01-02 US US09/753,752 patent/US20020058254A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5171684A (en) * | 1988-04-05 | 1992-12-15 | Amgen Inc. | Bioconversions catalyzed by the toluene monooxygenase of Pseudomanas mendocina KR-1 |
US5712146A (en) * | 1993-09-20 | 1998-01-27 | The Leland Stanford Junior University | Recombinant combinatorial genetic library for the production of novel polyketides |
US5958672A (en) * | 1995-07-18 | 1999-09-28 | Diversa Corporation | Protein activity screening of clones having DNA from uncultivated microorganisms |
Also Published As
Publication number | Publication date |
---|---|
US6168919B1 (en) | 2001-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6168919B1 (en) | Screening methods for enzymes and enzyme kits | |
EP1696025B1 (en) | Screening methods for enzymes and enzyme kits | |
US6054267A (en) | Method for screening for enzyme activity | |
US6344328B1 (en) | Method for screening for enzyme activity | |
US6030779A (en) | Screening for novel bioactivities | |
US6656677B2 (en) | Enzyme kits and libraries | |
AU720334B2 (en) | Method of screening for enzyme activity | |
US6368798B1 (en) | Screening for novel bioactivities | |
US6790605B1 (en) | Methods for obtaining a desired bioactivity or biomolecule using DNA libraries from an environmental source | |
AU767618B2 (en) | Screening methods for enzymes and enzyme kits | |
AU756201B2 (en) | Method of screening for enzyme activity | |
AU2007202329A1 (en) | Method of screening for enzyme activity | |
AU2003200812A2 (en) | Method of screening for enzyme activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DIVERSA CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHORT, JAY M.;REEL/FRAME:011965/0001 Effective date: 20010430 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |